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   2018  2019  
Indicator Definition Population Value 
(95%CI) 
N Value  
(95%CI) 
N 
Average coverage per cycle Mean of coverage in 
cycles 1,2,3 and 4 
Children aged 3-59 






Mean number of 
treatments per child 
Mean number of SMC 
treatments received  
Children aged 3-59 
months at cycle 1.  
2.87 
(2.49,3.24)  
1771 2.86  
(2.61,3.11) 
1893 
Coverage of 4 cycles % received 4 treatments Children aged 3-59 






Adherence % received 3 doses at 
last cycle (if treated) 
Children aged 3-59 






Reach of SMC programme % who received at least 
one treatment 
Children aged 3-59 






Coverage of cycle 1 % treated at cycle 1 Children aged 3-59 




(72.8%,87.1%)   
1893 
Coverage of cycle 2 % treated at cycle 2 Children aged 3-59 






Coverage of cycle 3 % treated at cycle 3 Children aged 3-59 






Coverage of cycle 4 % treated at cycle 4 Children aged 3-59 






Treatment of older children Mean number of SMC 
treatments received 




327 0.33  
(0.16,0.49) 
244 
Awareness of SMC dates % households heard 
date before last cycle 





LLIN use in children % slept under an LLIN 
last night 
Children 3-59 months 
who slept in the 






LLIN use (all ages) % slept under an LLIN All who slept in the 30.1% 5198 79.7% 4906 
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last night  household last night  (22.3,39.4) (71.8%,85.8%) 
ACCESS (% of population) % that could sleep 
under LLIN (if 2/net)  
All who slept in the 






% households with an LLIN  % households with an 
LLIN  





ACCESS (% households) % household with a LLIN 
for every two members 
All households, all who 






Caregiver knowledge about 
SMC 




1135 7.0  
(6.5,7.6) 
1068 
Reported CHW adherence 
to guidelines 
Mean score out of 8 Carers of a child who 
received SMC last cycle 
6.07  
(5.41,6.72) 
1135 7.6  
(7.3,7.8) 
1068 
SMC directly observed % of first doses 
administered by CHW 
Children 3-59 months 







Interval between cycle 1 
and cycle 2 
Mean difference 
between cycle dates 
Dates recorded on SMC 
cards 
34 days 1192 34 days 1261 
Interval between cycle 2 
and cycle 3 
Mean difference 
between cycle dates 
Dates recorded on SMC 
cards 
36 days 1150 32 days 1231 
Interval between cycle 3 
and cycle 4 
Mean difference 
between cycle dates 
Dates recorded on SMC 
cards 
29 days 969 33 days 686 
SMC card at survey % of children with SMC 
card 
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EXECUTIVE SUMMARY and RECOMMENDATIONS 
Background:  
Seasonal Malaria Chemoprevention (SMC) was introduced in Guinea in 2015 for children 
aged 3 months to 5 years, in 6 prefectures, and has been expanding to 8 prefectures in 
2016, and 10 in 2017 and 13 prefectures in 2018. SMC gives children a high level of personal 
protection from malaria. Evaluation of SMC programmes by the ACCESS-SMC project 
showed substantial reductions in malaria cases and malaria deaths in children, associated 
with introduction of SMC. High coverage of four monthly cycles is needed to maximise the 
impact of this intervention.  
 
In 2019, four cycles of SMC were delivered in Siguiri, Mandiana, Dabola, Kouroussa and 
Kankan prefectures, in July, August, September and October. Due to funding delays, only the 
first three cycles were implemented in Gaoual, Koundara, Mali, Lelouma, Labe, Koubia, 
Tougué and Dinguiraye. 
  
This survey was conducted to assess coverage of SMC and use of long-lasting insecticide-
treated bednets (LLINs) in 2019 in the 13 prefectures. The survey took place from 20 Dec 
2019 to 4 Jan 2020.  All children aged 3 months to 7 years were included in order to 
determine coverage in the target age group (aged at least 3months at the time of 
treatment, and aged not more than 59 months at cycle1) and to determine the proportion 
of children just above the recommended age limit who received treatment. Caregivers were 
interviewed about SMC treatments, dates of treatments were recorded from the SMC card, 
and SMC registers were checked to verify SMC treatments for children who did not have a 
card for inspection during the survey and for subset of children. In addition, all persons who 
slept in the household the night before the survey were listed, all bednets owned by the 
household were also listed and inspected, and for each person, the net they slept under, if 
any, was noted. A total of 1,893 children eligible to receive 4 treatments were surveyed in 
66 clusters. A total of 1038/1164 of households agreed to participate, a response rate of 
89%. 244 children too old to be eligible for SMC, were also surveyed.  
Administrative data:  
A total of almost 3 million treatments were administered in 2019 (2,986,364, of which 
454,030 (15.2%) to infants and 2,532,334 to children). The fourth cycle was not 
implemented in PMI areas. In most prefectures, the number of treatments administered per 
cycle was similar in each cycle. The variation was greatest (greater than 10% difference 
between the maximum and minimum per cycle) in Siguiri, Dabola and Kouroussa. Overall, 
1.4% of infant treatments and 0.4% of treatments to children 12-59 months, were vomited 
and a second dose administered. Infants were about 3 times more likely to vomit than older 
children. The risk of vomiting was highest in the first cycle, and lowest in the fourth cycle. If 
children are unwell they should be referred so that they can be tested and treated 
appropriately. However, referrals were relatively uncommon. Infants were twice as likely to 
be referred due to illness, than older children: 0.34% compared to 0.15%, risk ratio 2.3 
(95%CI 1.9,2.7). Referrals were more common during cycle 1 than other cycles. Children are 
excluded if they are outside the age range for SMC, or have a history of allergy to SMC 
drugs, or had taken sulfa-containing medicine or amodiaquine (apart from their last SMC) 
within the last 4 weeks. Infants were more likely to be excluded than children, and the 
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number excluded was, as is expected, highest in cycle 1. In cycle 1, 3.2% of infants were 
excluded in the PMI zone and 1.3% in the GF zone. Refusals: These may include children 
who would not take the medicine and children whose caregiver refused for them to have 
SMC. There were 288 refusals out of 3,010,437 children seen (about 1 per 10,000). Most of 
these were in the first cycle.  
Assessment of SMC status in the survey:  
Of children eligible for four SMC treatments, 88% had received an SMC card, and 68% had a 
card available for inspection in the survey. There was 83% agreement between caregiver 
report of the number of treatments and the number indicated on the record card. In 55 
clusters where SMC registers were available, an attempt was made to find entries in the 
SMC register for the children in the survey who did not have an SMC card, this was possible 
for 339/580 (58%) children, and for these children there was 79% agreement with the 
caregivers’ report. Allowing for the fact that most children who did not receive any SMC 
treatments will not be listed in the register, it appears that a high proportion of children 
who received SMC but did not have a card at the survey, were located in registers. We 
therefore recommend that registers be used in futures surveys to cross-check SMC status, 
for children who do not have a card, and for children who have a card.  
 
The SMC card is a record and reminder for the caregiver, so it is important that it is 
completed. Caregivers may use the card to check if their child’s treatments are complete, 
they could then seek treatment at the health centre if they missed the door-to-door 
campaign. Training of CHWs should emphasise the importance of recording treatments on 
the SMC card as well as in the register, and the need to remind caregivers to use and retain 
the card.  
Timing of SMC cycles:  
The median interval between treatments, based on dates recorded on SMC cards, in PMI 
areas (Gaoual, Koundara, Mali, Lelouma, Labe, Koubia, Tougué and Dinguiraye) was 35 days 
between cycle 1 and cycle 2, and 31 days between cycle 2 and 3, and in GF areas (Siguiri, 
Mandiana, Dabola, Kouroussa and Kankan), 33 days between cycle 1 and 2, 32 days 
between cycle 2 and 3, and 33 days between cycles 3 and 4. These intervals should be 
reduced to 28 days, as protection wanes rapidly after 4 weeks and malaria cases will 
increase in the 5th week. 
Awareness of SMC campaigns:  
Caregivers need to know the day when SMC will be distributed in their area in order to 
ensure they are available on that day. Overall, public informaitn campaigns appeared 
successful, 94.7% of households were aware of the SMC campaign and 92.4% said they 
knew in advance the date of the campaign for the cycle before the survey. However, 
communities in PMI areas were not aware that cycle 4 was not being implemented. 
Caregiver knowledge about SMC:  
Caregivers were asked if they understood key aspects of SMC, they scored 70% overall on a 
10-point questionnaire. Most caregivers (84%) knew that SMC is used to prevent malaria 
and most (81%) knew that there are 2 tablets to be taken on the first day and one on each 
of the next two days (84%). However there was a widespread view that SMC drugs could be 
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used for treatment if there was someone unwell in the household (only 44% of caregivers 
gave the correct response, that SMC drugs should not be used in this way), and only 62% of 
caregivers (62%) appreciated the importance of completing the 3-day course of treatment.  
Community Health Worker (CHW) adherence to SMC guidelines as reported by caregivers:  
CHW’s should check the child’s age, and before administering the treatment should ask 
about illness and refer the child if they are unwell, and should check the child has not had 
severe side effects to SMC before. They are also trained to explain to the caregiver how to 
administer the amodiaquine tablets on the next two days, and to advise caregivers about 
potential side effects and to bring the child to a health worker if they are become unwell 
after SMC. Caregivers of children who had received SMC, reported that the CHW generally 
followed these guidelines correctly, and the scores were notably better than when the same 
questions were asked after the 2018 campaign.  
Administration of SMC:  
In 97% of treated children, the first dose was directly observed (administered by the CHW, 
96.9%, or, in a small number, by the caregiver in the presence of the CHW, 0.4%). A small 
number of children (0.1%) received the first dose from the caregiver later, not observed by 
the CHW; the reason given was that the child was away at the time the CHW visited. And for 
2.6% of children, although the caregiver received the blister pack, the first dose was not 
administered. 
 
Reported adherence to the unsupervised doses of amodiaquine was very high. Of eligible 
children treated at cycle 4, caregivers reported that 96.1% received all three daily doses.  
 
Caregivers were asked if the child swallowed all the medicine, spat out some medicine, or 
vomitted all the medicine. Most responded the child swallowed the medicine without 
vomitting.  Of those who were treated, a total of 93.9% of children were reported to have 
received and swallowed the 3 daily doses without vomitting. 
Reasons for missed treatments:  
The most common reasons for not receiving SMC at cycle 4 were that the health worker did 
not visit (this mainly in PMI areas), or the caregiver was away in the fields or mines.  
Caregivers suggestions to improve the SMC programme:  
Caregivers were asked for suggestions to improve the SMC programme. There were 178 
responses, the points most commonly made were to include older age groups, build new 
health facilities, improve accessibility of remote areas, increase the quantity of SMC drugs, 
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SMC coverage in 2019:  
Children aged 3 to 59 months at the time of cycle 1 are eligible to receive SMC four times, 
and should receive all of these treatments to maximise their protection. Overall, 81% of 
children received SMC at cycle 1, 79% at cycle 2, 78% at cycle 3 and 49% at cycle 4. The 
mean number of treatments per child in 2019 was 2.9.  
 
Cycle 4 was not implemented in PMI areas, although there appeared to be some limited 
SMC distribution in some PMI areas, as some children had cycle 4 treatment dates for 2019 
marked on the SMC cards and in SMC registers. In GF areas, 58% of children received four 
SMC treatments and coverage was similar from month to month. There was some 
geographical variation in coverage, with notably lower coverage in Siguiri, with average 
monthly coverage of 44%. As this prefecture has the largest target population, this brings 
down the overall national figures of SMC coverage. Overall, 14.5% of children did not 
receive any SMC treatments, slightly less than in 2018 and 2017 (21%). Most of the children 
who did not receive any SMC are in Siguiri where 48% of children did not receive SMC, 
reflecting challenges of reaching children in mining areas.  
Treatment above the age limit:   
Children who are above 5 years of age at the time of the first SMC cycle, should not receive 
SMC. The dose has been calculated according to age and if older children are given the 
blister pack intended for the 12-59-month group, they may be under-dosed, this can select 
for resistance as parasites are exposed to sub-therapeutic doses of SMC drugs. 244 children 
6years and above were surveyed. 14% received an SMC card, 13% received SMC at least 
once, 10.9% received SMC in cycle 1, 9.6% in cycle 2, 10.2% in cycle 3 and 1.8% in cycle 4.  
Bednet use:  
Caregivers were asked about bednet use by their children on the night before the survey. 
Insecticide-treated bednets are the most cost-effective method of malaria prevention, SMC 
adds to this protection but does not replace the need to use bednets - ITNs or LLINs (long-
lasting insecticide-treated nets). In the survey after the 2017 SMC campaign, 43.6% of 
children in the survey (children eligible to receive SMC) were reported to have slept under a 
bednet the night before the survey. In the 2018 survey, 30.2% of children slept under a net 
the night before the survey. The survey was conducted after the main malaria season and 
bednet use may be lower at this time than in the main season but nevertheless bednet use 
was surprisingly low. There were notable variations with very low use of nets in some 
prefectures. In this 2019 survey, 86% (95%CI 79%,90%) of children slept under an LLIN the 
night before the survey. 97% of the nets the children were using were less than 8 months 
old according to caregivers. Coverage was similarly high in all areas except Siguiri where 71% 
slept under an LLIN. 
 
In addition, all persons who slept in the household the night before the survey were listed, all 
bednets owned by the household were also listed and inspected, and for each person, the net 
they slept under, if any, was noted. A total of 5,051 household members were surveyed in 
1038 households. A total of 4,906 slept in the household the night before the survey.  
Overall, 79.7% used a LLIN the night before the survey, compared to 28.7% in the 2018 
survey.  
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There was a notable dip in bednet use in children 5-14 years of age, 67% slept under an LLIN 
the night before the survey compared to 85% of 0-4year-olds and 81% of 15-19-year-olds. 
This is of concern as children stop receiving SMC when they are 5 years old (if they are more 
than 59 months old at the time of cycle 1). It is therefore especially important that these 
children use an LLIN. 
 
Net use was slightly lower among males than females (76.6% compared to 82.4%), and was 
higher in the lowest wealth ranking (87.9%) than the highest (77.3%). 
 
Of 1038 households surveyed, 89.8% had at least one LLIN but only 36.8% had one LLIN for  
every 2 persons. This compares with 39.7% had at least one LLIN and 13.1% had one LLIN  
for every 2 persons in the household, in 2018. 
 
Access to a LLIN, the percentage of the population who could sleep under a LLIN if there  




1. SMC during 2020:  
SMC delivery in Guinea has been highly successful. In 2019, apart from a problem 
implementing cycle 4 in PMI areas, high coverage has been maintained. The ACCESS-SMC 
project estimated that SMC in Guinea would be expected to avert about 1.2 deaths per 1000 
children treated per month. Thus the SMC programme in Guinea could have averted about 
4,000 deaths per year in recent years. It is therefore essential that efforts are made to 
maintain SMC during 2020, adapting the approach to minimise risks associated with the 
COVID19 epidemic. Effective delivery of SMC could have an even greater impact in 2020, in 
view of the likelihood that the population may seek to avoid attendance at health facilities 
during the epidemic, reducing access to malaria treatment, with consequently increased risk 
of mortality due to malaria.  
 
A coverage survey should be conducted again at the end of the 2020 season, to determine 
how successfully SMC was implemented in the context of the COVID19 outbreak.  
2. LLIN use in older children:  
There has been a marked increase in the use of LLINs following the successful distribution 
campaign in 2019. 85% of children under 5, and 80% of the population (of all ages) slept 
under a LLIN the night before the survey. However there was a notable dip in LLIN use in 
children aged 5-14 years. This is of concern, children who stop receiving SMC at age 5 need 
to be protected with an effective net, and specific efforts need to be made to ensure high 
levels of LLIN use in this age group.  
3. Number of SMC cycles:  
In some areas where SMC is currently being implemented, more than 4 cycles of SMC are 
needed to provide protection throughout the high risk period. Given the success of the 
current programme and high levels of coverage being achieved each month, extensions to 
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SMC should be considered, the most urgent priority is to provide 5 cycles in some of the 
current areas, and to expand the number of prefectures where SMC is implemented.  
4. Other adaptations of the SMC strategy:  
Inclusion of older children could be considered. This age group is included in SMC in 
neighbouring Senegal, where it has been found highly effective. In Guinea, surveillance, in 
selected hospitals and outpatient clinics, is needed to establish the burden of malaria in the 
6-10 age group.  
Combination with iCCM: SMC guidelines recommend that children who are unwell should 
be referred to that they can be assessed and given appropriate treatment. However in 2019, 
only 0.34% of infants and 0.15% of children 1-4 years were referred during SMC. The 
Government of Guinea has adopted a policy to implement a reformed integrated package of 
essential prevention and treatment services at community-level, through community-based 
agents de santé communautaire and relais communautaire, to reduce morbidity and mortality 
with a focus on rural populations. This provides an opportunity to ensure children who are 
unwell during SMC visits can be treated; these staff can also help to ensure high coverage of 
SMC as they are familiar with the local community and maintain a census list of the 
population. 
Screening for malnutrition during SMC visits has been piloted in some countries, but its 
effectiveness has not been evaluated. This merits further investigation. 
Delivery in mining areas: SMC coverage has been consistently low in mining areas, where 
caregivers were often away from their home on the day of the campaign. Delivery needs to 
be adapted in these areas to reach families involved mining activities. 
5. Monitoring of the efficacy of SMC  
should be established. This can be done using case control studies, which measure clinical 
protection, combined with monitoring of molecular markers of resistance to SMC drugs.  
6. Strengthen pharmacovigilance.  
As well as working to strengthen the PV system nationally, safety monitoring should be 
strengthened in selected SMC areas where training and supervision can be provided to 
ensure that health staff recognise events and report suspected adverse drug reactions.  
7. Measuring impact of SMC:  
HMIS data on malaria should be regularly assessed to track the impact of the SMC 
programme on malaria cases, and malaria deaths in hospital. This has been difficult as the 
structure of datasets prior to DHIS2 do not facilitate comparison of the same facilities year 
to year but will be possible for new SMC areas where DHSI2 data are available for at least a 
year prior to SMC introduction.  
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SOMMAIRE EXÉCUTIF et RECOMMANDATIONS 
Contexte : La chimio prévention du paludisme saisonnier (CPS or SMC) a été introduite en 
Guinée en 2015 pour les enfants âgés de 3 mois à 5 ans, dans 6 préfectures, et s'est étendue 
à 8 préfectures en 2016, 10 en 2017 et 13 préfectures en 2018. La CPS offre aux enfants un 
niveau élevé de protection personnelle contre le paludisme. L'évaluation 
des programmes de la CPS par le projet ACCESS-SMC a montré des réductions substantielles 
des cas de paludisme et des décès dus au paludisme chez les enfants, associés à 
l'introduction de la CPS. Une couverture élevée de quatre cycles mensuels est nécessaire 
pour maximiser l'impact de cette intervention. 
  
En 2019, quatre cycles de la CPS ont été livrés dans les préfectures de 
Siguiri, Mandiana, Dabola, Kouroussa et Kankan, en juillet, août, septembre et octobre. En 
raison du retard de financement, seuls les trois premiers cycles ont été mis en œuvre 
à Gaoual, Koundara, Mali, Lelouma, Labe, Koubia, Tougué et Dinguiraye. 
  
Cette enquête a été menée pour évaluer la couverture de la CPS et l'utilisation de 
moustiquaires imprégnés d'insecticide à longue durée d’action (MILDA) en 2019 dans les 13 
préfectures. L'enquête a eu lieu du 20 décembre 2019 au 04 janvier 2020. Tous les enfants 
âgés de 3 mois à 7 ans ont été inclus afin de déterminer la couverture dans le groupe d'âge 
cible (âgés d'au moins 3 mois au moment du traitement et de plus 59 mois au cycle 1) et 
pour déterminer la proportion d'enfants juste au-dessus de la limite d'âge recommandée 
qui ont reçu un traitement. Les mères et les gardiens d’enfants ont été interrogés sur les 
traitements de la CPS, les dates des traitements ont été enregistrées sur la carte CPS et les 
registres CPS ont été utilisés pour vérifier les traitements CPS pour les enfants qui n'avaient 
pas de carte pendant l'enquête et pour un sous-ensemble d'enfants. De plus, toutes les 
personnes qui dormaient dans le ménage la nuit avant l'enquête ont été répertoriées, 
toutes les moustiquaires appartenant au ménage ont également été répertoriés et 
inspectés, et pour chaque personne, la moustiquaire sous laquelle ils ont dormi a été noté, 
le cas échéant. Au total, 1 893 enfants éligibles pour recevoir 4 traitements ont été 
interrogés dans 66 grappes. Au total, 1038/1164 des ménages ont accepté de participer, soit 
un taux de réponse de 89%.  244 enfants trop âgés pour être éligibles à la 
CPS ont également été interrogés. 
  
Données administratives : au total, près de 3 millions de traitements ont été administrés en 
2019 (2986364, dont 454030 (15,2%) aux nourrissons et 2532334 aux enfants). Le 
quatrième cycle n'a pas été mis en œuvre dans les zones PMI. Dans la plupart des 
préfectures, le nombre de traitements administrés par cycle était similaire dans chaque 
cycle. La variation était la plus importante (différence supérieure à 10% entre le maximum 
et le minimum par cycle) à Siguiri, Dabola et Kouroussa. Dans l'ensemble, 1,4% des 
traitements pour nourrissons et 0,4% des traitements pour enfants de 12 à 59 mois ont été 
vomis et une deuxième dose a été administrée. Les nourrissons étaient environ 3 fois plus 
susceptibles de vomir que les enfants plus âgés. Le risque de vomissement était le plus élevé 
au premier cycle et le plus faible au quatrième cycle. Si les enfants ne sont pas bien, ils 
doivent être référés afin qu'ils puissent être testés et traités de manière 
appropriée. Cependant, les renvois étaient relativement rares. Les nourrissons étaient deux 
fois plus susceptibles d'être référés pour cause de maladie que les enfants plus âgés : 0,34% 
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par rapport à 0,15%. Les renvois étaient plus fréquents au cours du cycle 1 que les autres 
cycles. Les enfants sont exclus s'ils sont en dehors de la tranche d'âge pour la CPS, ou si vous 
avez des antécédents d'allergie aux médicaments CPS, ou si vous avez pris des sulfamides ou 
de l'amodiaquine (en dehors de leur dernier CPS) au cours des 4 dernières semaines. Les 
nourrissons étaient plus susceptibles d'être exclus que les enfants, et le nombre d'exclus 
était, comme prévu, le plus élevé au cycle 1. Au cycle 1, 3,2% des nourrissons étaient exclus 
dans la zone PMI et 1,3% dans la zone GF. En terme de refus, il peut s’agir d’enfants qui ne 
prendraient pas le médicament et d’enfants dont la personne qui s’occupe de l'enfant a 
refusé qu’ils aient la CPS. Il y a eu 288 refus sur 3010437 enfants vus (environ 1 pour 10 
000). La plupart d'entre eux étaient dans le premier cycle. 
  
Évaluation du statut CPS dans l'enquête : Parmi les enfants éligibles à quatre traitements 
CPS, 88% avaient reçu une carte CPS et 68% avaient une carte disponible pour inspection 
dans l'enquête. Il y avait 83% d'accord entre le rapport du soignant sur le nombre de 
traitements et le nombre indiqué sur la fiche d'enregistrement. Dans 55 grappes où des 
registres CPS étaient disponibles, une tentative a été faite pour trouver des entrées dans le 
registre CPS pour les enfants de l'enquête qui n'avaient pas de carte CPS, cela a été possible 
pour 339/580 (58%) enfants, et pour ceux-ci les enfants, il y avait 79% d'accord 
avec le rapport des soignants . Compte tenu du fait que la plupart des enfants qui n'ont reçu 
aucun traitement CPS ne seront pas répertoriés dans le registre, il apparaît qu'une forte 
proportion d'enfants qui ont reçu de la CPS mais qui n'avaient pas de carte lors de l'enquête 
se trouvaient dans les registres. Nous recommandons donc que les registres soient utilisés 
dans les enquêtes futures pour recouper le statut CPS pour les enfants qui n'ont pas de 
carte et pour les enfants qui ont une carte. 
  
La carte CPS est un enregistrement et un rappel pour la mère et le gardien d’enfants, il est 
donc important qu'elle soit remplie. La mère et le gardien d’enfants peuvent utiliser la carte 
pour vérifier si les traitements de leur enfant sont terminés, ils pourraient alors demander 
un traitement au centre de santé s'ils ont raté la campagne de porte à porte. La formation 
des ASC devrait souligner l'importance de l'enregistrement des traitements sur la carte CPS 
ainsi que dans le registre, et la nécessité de rappeler aux la mère et le gardien d’enfants 
d'utiliser et de conserver la carte. 
  
Moment des cycles CPS : L'intervalle médian entre les traitements, basé sur les dates 
enregistrées sur les cartes CPS, dans les zones PMI (Gaoual, Koundara, Mali, Lélouma, Labé, 
Koubia, Tougué et Dinguiraye) était de 35 jours entre le cycle 1 et le cycle 2, et 31 jours 
entre les cycles 2 et 3, et dans les zones de GF (Siguiri, Mandiana, Dabola, Kouroussa et 
Kankan), 33 jours entre les cycles 1 et 2, 32 jours entre les cycles 2 et 3 et 33 jours entre les 
cycles 3 et 4. Ces intervalles doivent être réduits à 28 jours, car la protection diminue 
rapidement 4 semaines et les cas de paludisme augmenteraient au cours de la 5e semaine. 
  
Sensibilisation aux campagnes de la CPS : les mères et les gardiens d’enfants doivent 
connaître le jour où la CPS sera distribuée dans leur région afin de s'assurer qu'ils 
sont disponibles ce jour-là. Dans l'ensemble, les campagnes d'information du public ont 
semblé être fructueuses, 94,7% des ménages étaient au courant de la campagne CPS 
et 92,4% ont déclaré connaître à l'avance la date de la campagne pour le cycle précédant 
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l'enquête. Cependant, les communautés des zones PMI ne savaient pas que le cycle 4 n'était 
pas mis en œuvre. 
  
Connaissances des soignants sur la CPS : on a demandé aux soignants s'ils comprenaient les 
aspects clés de la CPS, ils ont obtenu un score global de 70% sur un questionnaire en 10 
points. La plupart des mères et gardiens d’enfants (84%) savaient que le CPS est utilisé pour 
prévenir le paludisme et la plupart (81%) savaient qu'il y avait 2 comprimés à prendre le 
premier jour et un pour chacun des deux jours suivants (84%). Cependant, il y avait une 
opinion largement répandue que les médicaments CPS pouvaient être utilisés pour le 
traitement s'il y avait une personne malade dans le ménage (seulement 44% des mères ou 
gardiens d’enfants ont donné la bonne réponse, que les médicaments CPS ne devraient pas 
être utilisés de cette manière), et seulement 62% des mères ou gardiens d’enfants (62%) ont 
apprécié l'importance de terminer le traitement de 3 jours. 
  
Adhésion des agents de santé communautaire (ASC) aux lignes directrices de la CPS, telles 
que rapportées par les mères ou gardiens d’enfants : les ASC doivent vérifier l'âge de 
l'enfant, et avant d'administrer le traitement, ils doivent poser des questions sur la maladie 
et orienter l'enfant en cas de malaise, et doivent vérifier que l'enfant n'a pas eu avant 
d’effets secondaires graves à la CPS. Ils sont également formés pour expliquer aux mères ou 
gardiens d’enfants comment administrer les comprimés d'amodiaquine au cours des deux 
prochains jours, et pour conseiller les mères ou gardiens d’enfants sur les effets secondaires 
potentiels et pour amener l'enfant à un agent de santé en cas de malaise après CPS. Les 
mères ou gardiens d'enfants qui ont reçu la CPS ont indiqué que les ASC respectaient 
généralement correctement les directives de la CPS et que les scores étaient nettement 
meilleurs que lorsque les mêmes questions avaient été posées après la campagne de 2018. 
  
Administration de la CPS : chez 97% des enfants traités, la première dose a été directement 
observée (administrée par l’agent de santé communautaire, 96,9%, ou, en petit nombre, par 
le soignant en présence du CHW, 0,4%). Un petit nombre d'enfants (0,1%) ont reçu, non 
observée par l'ASC plus tard, la première dose de la mère ou du gardien d’enfants ; la raison 
invoquée était que l'enfant était absent au moment de la visite de l'ASC. Et pour 2,6% des 
enfants, bien que la mère ou le gardien d’enfants a reçu les médicaments, le restant de la 
dose n'a pas été administré. 
  
L'adhésion rapportée aux doses non surveillées d'amodiaquine était très élevée. Parmi les 
enfants admissibles traités au cycle 4, les mères et gardiens d’enfants ont indiqué que 96,1% 
avaient reçu les trois doses quotidiennes. 
  
On a demandé aux mères ou gardiens d’enfants si l'enfant avait avalé tout le médicament, 
craché le médicament ou vomi tout le médicament administré. La plupart ont répondu que 
l'enfant avait avalé le médicament sans vomir. Parmi ceux qui ont été traités, 93,9% des 
enfants auraient reçu et avalé les 3 doses quotidiennes sans vomir. 
  
Raisons des traitements manqués : Les raisons les plus courantes pour ne pas recevoir la 
CPS au cycle 4 étaient que l'agent de santé n'était pas venu (principalement dans les zones 
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PMI), ou la mère ou le gardien d’enfants était absent à la maison, présent dans les champs 
ou dans les mines. 
  
Suggestions des soignants pour améliorer le programme de la CPS : On a demandé aux 
mères ou gardiens d’enfants des suggestions pour améliorer le programme CPS. Il y a eu 178 
réponses, les points les plus souvent avancés étant d'inclure des groupes d'âge plus avancés, 
de construire de nouveaux établissements de santé, d'améliorer l'accessibilité des zones 
reculées, d'augmenter la quantité de médicaments CPS, d'augmenter le nombre de mois de 
CPS, de fournir de la CPS dans les mines, et de fournir plus de moustiquaires. 
  
Couverture de la CPS en 2019 : les enfants âgés de 3 à 59 mois au moment du cycle 1 sont 
éligibles pour recevoir la CPS quatre fois et devraient recevoir tous ces traitements pour 
maximiser leur protection. Globalement, 81 % des enfants ont reçu la CPS au cycle 1,79% au 
cycle 2, 78 % au cycle e 3 et 49 % au cycle 4. Le nombre moyen de traitements par enfant en 
2019 était de 2,9. 
  
Le cycle 4 n'a pas été mis en œuvre dans les zones PMI, bien qu'il semble y avoir une 
distribution limitée de la CPS dans certaines zones PMI, car certains enfants ont marqué les 
dates de traitement du cycle 4 pour 2019 sur les cartes CPS et dans les registres de la 
CPS. Dans les zones de GF, 58% des enfants ont reçu quatre traitements de la CPS et la 
couverture était similaire d'un mois à l'autre. Il y avait une certaine variation géographique 
dans la couverture, avec notamment une couverture plus faible à Siguiri, avec une 
couverture mensuelle moyenne de 44%. Cette préfecture ayant la population cible la plus 
importante, cela fait baisser les chiffres nationaux globaux de la couverture de la CPS. Dans 
l'ensemble, 14,5% des enfants n'ont reçu aucun traitement de la CPS, un peu moins qu'en 
2018 et 2017 (21%). La plupart des enfants qui n'ont reçu aucun traitement de la CPS se 
trouvent à Siguiri où 48% des enfants n'ont pas reçu de la CPS, ce qui reflète les difficultés à 
atteindre les enfants dans les zones minières. 
  
Traitement au-dessus de la limite d'âge : les enfants âgés plus de 5 ans au moment du 
premier cycle CPS ne doivent pas recevoir la CPS. La dose a été calculée en fonction de l'âge 
et si les enfants de plus de 5 ans reçoivent le blister destiné au groupe de 12 à 59 mois, ils 
peuvent être sous-dosés, ce qui peut augmenter la sélection de parasites résistants, car les 
parasites sont exposés à des doses thérapeutiques de médicaments CPS. En tout 244 
enfants de 6 ans et plus ont été interrogés, dont 14 % ont reçu une carte CPS, 13 % ont reçu 
CPS au moins une fois, 10,9 % ont reçu la CPS au cycle 1, 9,6% au cycle 2, 10,2% au cycle e 3 
et 1,8% au cycle 4. 
  
Utilisation des moustiquaires : les mères ou gardiens d’enfants ont été interrogés sur 
l'utilisation des moustiquaires par leurs enfants la nuit précédant l'enquête. Les 
moustiquaires imprégnées d'insecticide constituent la méthode de prévention du paludisme 
la plus rentable, la CPS s'ajoutent à cette protection mais ne remplacent pas la nécessité 
d'utiliser les moustiquaires - MILDA (moustiquaires imprégnées d'insecticides à longue 
durée d’action). Dans l'enquête après la campagne CPS de 2017, 43,6% des enfants 
interrogés (enfants éligibles pour recevoir la CPS) auraient dormi sous une moustiquaire la 
nuit précédant l'enquête. Dans l'enquête 2018, 30,2% des enfants ont dormi sous une 
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moustiquaire la nuit précédant l'enquête. L'enquête a été menée après la saison de haute 
transmission de paludisme et l'utilisation des moustiquaires peut être plus faible à ce 
moment que pendant la saison de haute transmission, néanmoins l'utilisation des 
moustiquaires était étonnamment faible. Il y avait des variations notables avec une très 
faible utilisation de moustiquaires dans certaines préfectures. Dans cette enquête de 2019, 
86des enfants dormaient sous une MILDA la nuit précédant l'enquête. 97% des 
moustiquaires que les enfants utilisaient avaient moins de 8 mois selon les mères ou 
gardiens d’enfants. La couverture était également élevée dans toutes les régions, à 
l'exception de Siguiri où 71% dormaient sous une MILDA. 
  
De plus, toutes les personnes qui ont dormi dans le ménage la nuit avant l'enquête ont été 
répertoriées, toutes les moustiquaires appartenant au ménage ont également été répertoriées 
et inspectées, et pour chaque personne, la moustiquaire sous laquelle ils ont dormi, le cas 
échéant, a été notée. Au total, 5 051 membres du ménage ont été interrogés dans 1 038 
ménages. Au total, 4 906 personnes ont dormi dans la maison la nuit précédant 
l'enquête.  Dans l'ensemble, 79,7% ont utilisé une MILDA la veille de l'enquête, 
contre 28,7% dans l'enquête de 2018. 
  
Il y avait une baisse notable de l'utilisation des moustiquaires chez les enfants de 5 à 14 ans, 
67% dormaient sous une MILDA la nuit précédant l'enquête, contre 85% des 0-4 ans et 81% 
des 15-19 ans. 
 
Cela est préoccupant car les enfants cessent de recevoir la CPS lorsqu'ils ont 5 ans (s'ils ont 
plus de 59 mois au moment du cycle 1). Il est donc particulièrement important que ces 
enfants utilisent une MILDA. 
  
La consommation nette était légèrement inférieure chez les hommes que chez les femmes 
(76,6% contre 82,4%) et était plus élevée dans le classement de richesse le plus bas (87,9%) 
que dans le classement le plus élevé (77,3%). 
  
Sur 1038 ménages interrogés, 89,8% avaient au moins une MILDA mais seulement 36,8% en 
avaient une pour toutes les 2 personnes. Cela se compare à 39,7% avait au moins une MILD 
et 13,1% avait une MILDA pour 2 personnes dans le ménage, en 2018. 
  
Accès à une MILDA, le pourcentage de la population qui pourrait dormir sous une MILDA s'il 
y en a, a été deux personnes par moustiquaire, était de 25,4% en 2018. Cela est passé à 
68,2% dans l'enquête actuelle. 
  
Recommandations : 
1. CPS en 2020 : la livraison de la CPS en Guinée a connu un grand succès. En 2019, en 
dehors d'un problème de mise en œuvre du cycle 4 dans les zones PMI, une couverture 
élevée a été maintenue. Le projet ACCESS-SMC a estimé que la CPS en Guinée devraient 
éviter environ 1,2 décès pour 1000 enfants traités par mois. Ainsi, le programme CPS en 
Guinée aurait pu éviter environ 4 000 décès par an ces dernières années. Il est donc 
essentiel que des efforts soient faits pour maintenir la CPS en 2020, en adaptant l'approche 
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pour minimiser les risques associés à l'épidémie de COVID19. La prestation efficace de la 
CPS pourrait avoir un impact encore plus important en 2020, compte tenu de la probabilité 
que la population cherche à éviter de fréquenter les établissements de santé pendant 
l'épidémie, réduisant l'accès au traitement antipaludique, avec par conséquent un risque 
accru de mortalité due au paludisme. 
  
Une enquête de couverture devrait être menée à nouveau à la fin de la saison 2020, afin de 
déterminer le succès de la mise en œuvre de la CPS dans le contexte de l'épidémie de 
COVID19. 
  
2. Utilisation de MILD chez les enfants plus âgés : il y a eu une augmentation marquée de 
l'utilisation des MILDA après la campagne de distribution réussie en 2019. 85% des enfants 
de moins de 5 ans et 80% de la population (de tous âges) ont dormi sous une MILDA la nuit 
avant l'enquête. Cependant, il y avait une baisse notable de l'utilisation des MILDA chez les 
enfants âgés de 5 à 14 ans. Cela est préoccupant, les enfants qui cessent de recevoir de la 
CPS à l'âge de 5 ans doivent être protégés avec une moustiquaire efficace, et des efforts 
spécifiques doivent être faits pour garantir des niveaux élevés d'utilisation des MILDA dans 
ce groupe d'âge. 
  
3. Nombre de cycles de la CPS : Dans certaines zones où la CPS est actuellement mise en 
œuvre, plus de 4 cycles de la CPS sont nécessaires pour assurer une protection tout au long 
de la période à haut risque. Compte tenu du succès du programme actuel et des niveaux 
élevés de couverture atteints chaque mois, des extensions de la CPS devraient être 
envisagées, la priorité la plus urgente est de prévoir 5 cycles dans certaines des zones 
actuelles et d'augmenter le nombre de préfectures où la CPS est mis en œuvre. 
  
4. Autres adaptations de la stratégie de la CPS : 
L'inclusion d'enfants plus âgés pourrait être envisagée. Ce groupe d'âge est inclus dans la 
CPS au Sénégal voisin, où il s'est révélé très efficace. En Guinée, la surveillance, dans 
les hôpitaux et les cliniques externes sélectionnés, est nécessaire pour établir la charge du 
paludisme dans la tranche d'âges de 6-10. 
Combinaison avec la Prise en charge intégrée des maladies de l'enfance (PCIME):  
Les lignes directrices de la CPS recommandent que les enfants malades soient référés afin 
qu'ils puissent être évalués et recevoir un traitement approprié. Cependant, en 2019, 
seulement 0,34% des nourrissons et 0,15% des enfants de 1 à 4 ans ont été référés pendant 
la CPS. Le gouvernement de Guinée a adopté une politique visant à mettre en œuvre un 
ensemble intégré réformé de services essentiels de prévention et de traitement au 
niveau communautaire, par le biais d'agents de santé communautaire et de relais 
communautaires, afin de réduire la morbidité et la mortalité en mettant l'accent sur la 
population rurale. Cela permet de garantir le traitement des enfants qui ne se sentent pas 
bien lors des visites pour la CPS ; ce personnel peut également aider à assurer une 
couverture élevée de la CPS car il connaît la communauté locale et tient une liste de 
recensement de la population. 
Le dépistage de la malnutrition lors des visites pour la CPS a été expérimenté dans certains 
pays, mais son efficacité n'a pas été évaluée. Cela mérite une enquête plus approfondie. 




Accouchement dans les zones minières : la couverture de la CPS a toujours été faible dans 
les zones minières, où les mères et gardiens d’enfants étaient souvent loin de leur domicile 
le jour de la campagne. La livraison doit être adaptée dans ces zones pour atteindre les 
familles impliquées dans les activités minières. 
  
5. Une surveillance de l'efficacité de la CPS doit être établie. Cela peut être fait en utilisant 
des études cas-témoins, qui mesurent la protection clinique, combinée à la surveillance des 
marqueurs moléculaires de la résistance aux médicaments CPS. 
  
6. Renforcer la pharmacovigilance. En plus de travailler au renforcement du système 
photovoltaïque au niveau national, la surveillance de la sécurité devrait être renforcée dans 
certains domaines de la CPS où la formation et la supervision peuvent être assurées pour 
s'assurer que le personnel de santé reconnaît les événements et signale les effets 
indésirables suspectés des médicaments. 
  
7. Mesurer l'impact de la CPS : les données d’enquête indicateurs multiples sur le paludisme 
doivent être régulièrement évaluées pour suivre l'impact des programmes de la CPS sur 
les cas de paludisme et les décès dus au paludisme à l'hôpital. Cela a été difficile car la 
structure de l’ensembles de données avant DHIS2 ne facilite pas la comparaison des mêmes 
structures de sante d'année en année mais sera possible dans les nouvelles zones de la CPS 
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BACKGROUND AND OBJECTIVES 
The Republic of Guinea is one of 18 high burden countries which account for more than 80% 
of deaths due to malaria worldwide (WHO 2019). Malaria occurs year-round with a highly 
seasonal pattern in the north of the country. The main vectors are Anopheles gambiae, An. 
funestus, An. melas and An. arabiensis. The prevalence of malaria infection in children in a 
national survey in 2016, showed that 22% of children aged 6 to 59 months, surveyed 
between August and November, tested positive for Plasmodium falciparum by rapid 
diagnostic test indicating current or recent infection and 15% were positive by microscopy. 
The prevalence of anaemia (Hb<8g/dL) was 18% (Table 1). WHO estimated* there were 
3,524,261 cases of malaria and 8,203 deaths caused by malaria in 2018 in a population of 
12.4million. The estimated 2019 population is 12.8million in total including 2.1million 
children under 5 years of age (United Nations Department of Economic and Social Affairs, 
2019). Under-5 mortality was estimated to be 111 per 1000 live births in the 2018 DHS 
survey (over the 5-year period with midpoint 2016), and 80.7 (for the 5-year period with 
midpoint 2018) in the UN projections (United Nations Department of Economic and Social 
Affairs, 2019).  
 
Malaria treatment guidelines require patients suspected to have malaria to be tested before 
being treated. Malaria diagnosis and artemisinin combination treatment (ACT) have been 
free in the public sector for all age groups since 2010 for ACT treatment and since 2012 for 
diagnosis. The first-line antimalarial is amodiaquine-artesunate, except in areas where 
Seasonal Malaria Chemoprevention (SMC) is used, where it has been replaced with 
artemether-lumefantrine. Therapeutic efficacy testing in 2015-2016 indicated both drugs 
retain a high level of effficacy, and further monitoring is being undertaken (Camara et al. 
2019). Since 2009, long-lasting insecticide-treated bednets (LLINs) have been provided free 
of charge to all age groups. Intermittent preventive treatment in pregnancy using 
sulfadoxine-pyrimethamine has been recommended since 2005. Indoor Residual Spraying 
and larviciding are not part of the national malaria control strategy. The  Demographic and 
Health Survey (DHS) in 2018, showed that coverage  of key primary health interventions 
(childhood vaccination, access to prompt and effective case management of childhood 
illnesses, and prenatal and postnatal care) were low (Table 2). In 2017, the Government of 
Guinea adopted a policy to implement a reformed integrated package of essential 
prevention and treatment services at community-level, to reduce morbidity and mortality 
with emphasis on the rural population, and a strategic plan (2018-2022) and three-year 
operational plan (2018-2020) were developed to guide implementation (Ministere de la 
Sante, Republique de Guinea, 2018a,b). 
 
Seasonal Malaria Chemoprevention (SMC) was introduced in 2015. SMC involves the 
administration of a treatment course of sulfadoxine-pyrimethamine plus amodiaquine once 
a month to children aged 3–59 months during the high risk period each year to prevent 
malaria (WHO 2013). SMC was introduced initially in 6 prefectures, scaling up to 13 
prefectures by 2018. A survey in the 13 prefectures with SMC in 2018 showed that 79% of 
children received SMC at least once, and 61% received four treatments. There were 
geographical variations with lower coverage in mining areas. Use of bednets (LLINs) was 
low, only 30% of children slept under an LLIN the night before the survey, 40% of 
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households owned an LLIN, 13% of households had one LLIN per 2 persons, and 25% of the 
population had access to an LLIN (Loua and Milligan 2019).  
 
Using predictions from the Imperial College malaria model, the ACCESS-SMC project 
estimated that SMC in Guinea would be expected to avert about 1.2 deaths per 1000 
children treated per month. Thus the SMC programme in Guinea in 2018, which 
administered 3.4million treatments in 2018, could have averted about 4,000 deaths. 
 
The present survey was conducted in the same 13 prefectures at the end of the 2019 
transmission season to determine SMC coverage and use of LLINs, following national 
distribution of LLINs in 2019. The survey aimed to determine the percentage of children who 
received SMC in each cycle, the percentage who received the full four treatments, the 
adherence to the SMC regimen, and the use of insecticide-treated bednets by all household 
members, and to ask caregivers of children who did not receive four treatments, the 
reasons their children missed SMC treatments. During the survey, the feasibility of using 
SMC registers to validate caregiver report of SMC treatments, was investigated. 
Table 1: Prevalence of malaria infection, anaemia and malnutrition, from DHS surveys in 
Aug-Nov 2016. 
Region P.falciparum Other plasmodium Anaemia Stunting Wasting  
Slide RDT (vivax,malaria,ovale) RDT Hb<8g/dL (ht for age, z<-2) (wt for age, z <-2) 
Boke 8.0% 12.9% 3.9% 14.5% 39.1% 20.4% 
Conakry 1.9% 1.4% 0.4% 13.6% 20.5% 11.5% 
Faranah 24.9% 31.7% 6.0% 24.6% 29.0% 17.1% 
Kankan 19.4% 19.1% 7.3% 21.9% 30.5% 19.7% 
Kindia 10.3% 21.6% 2.6% 21.0% 29.0% 15.1% 
Labe 7.9% 12.7% 1.3% 12.5% 32.5% 18.4% 
Mamou 18.4% 31.5% 1.0% 14.0% 27.0% 16.1% 
Nzerekore 30.2% 46.7% 4.5% 16.7% 33.5% 12.2% 
TOTAL 15.3% 21.9% 3.6% 17.5% 30.3% 16.3% 
Source: Institut National de la Statistique (INS), Programme National de Lutte contre le Paludisme (PNLP) et ICF (2017). 
 
Table 2: Vaccination coverage and bednet coverage, DHS 2018: 
Region DTP3 Measles 1 All basic vaccines* Households  
with an LLIN 
Households with  
1 LLIN per 2 persons 
Boke 29.6% 32.5% 16.9% 52.9% 22.7% 
Conakry 55.1% 56.6% 36.5% 24.8% 7.8% 
Faranah 39.4% 36.2% 20.6% 52.1% 13.6% 
Kankan 46.6% 58.1% 36.2% 33.1% 8.1% 
Kindia 39.8% 21.1% 11.7% 48.7% 25.3% 
Labe 19.2% 17.1% 8.4% 54.0% 24.4% 
Mamou 24.5% 30.8% 13.3% 45.5% 17.3% 
Nzerekore 51.4% 50.0% 35.0% 49.5% 17.1% 
TOTAL 40.2% 39.5% 23.9% 43.9% 16.7% 
* BCG, three doses of pentavalent (DTP-HepB-Hib), three doses of oral polio (not including the dose at birth) and one dose 
of measles vaccine. Source: Institut National de la Statistique (INS) et ICF. (2018) 
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Description of Seasonal Malaria Chemoprevention  
SMC involves administration of a course of treatment of sulfadoxine-pyrimethemine plus 
amodiaquine over three days, once per month for four months of the malaria transmission 
season, to prevent malaria illness. Children aged at least 3 months and less than 5 years of 
age are eligible to receive SMC, however children who were under 5 years of age at the first 
month continue to receive all four monthly treatments even if they reach the age of 5 
during the 4-month period of SMC distribution. Each monthly treatment consists of a dose 
of sulfadoxine-pyrimethamine and a dose of amodiaquine, administered on the first day, 
and a dose of amodiaquine on each of the next two days. The drugs are distributed by 
community health workers (CHWs) who visit door to door to administer the first day’s doses 
and leave the blister pack with the caregiver with instructions to administer the remaining 
amodiaquine doses on each of the next two days. CHWs check the age of the child and 
select the appropriate blister pack (lower dose for infants, higher dose for children 12-59 
month), ask about allergies to SMC drugs, check whether the child has been given 
sulfadoxine-pyrimethamine or amodiaquine or any sulfa-containing antibiotic in the last 4 
weeks, and check if the child has a fever. Children are eligible if they do not have known 
allergies to the drugs, have not been given amodiaquine of sulfa-containing medication in 
the last 4 weeks, and are not unwell. Children who are unwell should be referred to the 
nearest health centre where they can be appropriately treated, including treatment with an 
ACT if they have malaria. If they do not have malaria, they may receive SMC at the clinic. 
CHWs should also remind caregivers to bring the child to the health centre if the child 
becomes unwell at any time after taking SMC, and that the child can still develop malaria 
and so the guidance to seek treatment promptly in the case of fever should continue to be 
followed, and all household members should sleep under a treated bednet. Each course of 
SMC treatment provides about 90% protection from malaria for 28 days so that four 
treatments one month apart can provide a high degree of personal protection for 4 months. 
Introduction of SMC with high coverage has been found to reduce the incidence of malaria, 
severe malaria, and malaria deaths, substantially. To maximise the impact of the 
intervention, it is important that the first SMC cycle is timed to start at the beginning of the 
main transmission period; cycles should take place at monthly intervals; high coverage of 4 
monthly treatments should be achieved; and caregivers should ensure children adhere to 
the daily regimen each month. Insecticide treated bednets should continue to be used, SMC 
should be an additional measure not a substitute for bednets. The survey therefore 
assessed bednet use by children and other members of the household. 
Scaling-up of SMC in Guinea  
SMC was introduced in Guinea in 2015, in 6 prefectures with a target population of 210 107 
children. The area covered was increased to 8 prefectures in 2016, 10 in 2017, and 13 in 
2018 (Tables 3-4 and Figure 1). In 2018 the target population of children was 825 994, an 
increase of about 40% compared to the target number in 2017. Siguiri and Kankan are the 
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Table 3: Expansion of SMC in Guinea 2015-2019 
Prefecture 2015 2016 2017 2018 2019 
Dinguiraye X X X X X 
Gaoual X X X X X 
Koubia X X X X X 
Koundara X X X X X 
Mali X X X X X 
Tougue X X X X X 
Mandiana X X X X 
Siguiri 
 
X X X X 
Labe 
  
X X X 
Lelouma 
  
X X X 
Dabola 
   
X X 
Kankan 





Target population 210107 438123 591071 825994 818502 
 
 
The delivery of SMC from 2015 to 2018 is summarised in the table below. The estimated 
percentage of children who received four SMC treatments was 57% in 2015 and 73% in 2016 
and 63% in 2017 and 61% in 2018.   
 
Table 4: SMC delivery in Guinea 2015-2019 


















2015 6 210,107 805,131 80% 94% 57% 197,501 119,761 
2016 8 438,123 1,750,224 88% 96% 73% 420,598 319,830 
2017 10 591,071 2,303,709 73% 79% 63% 466,946 372,375 
2018 13 825,994 3,356,780 72% 79% 61% 655,013 501,378 
2019 13  818,502† 2,986,364 72% 86% 41% 699,819 338,860 
*The target population multiplied by the estimate proportion of children who received at least one SMC treatment. #The 
target population multiplied by the proportion of children who received four treatments.  †Population updated based on 
bednet campaign estimates. 
‡Sampling for the 2015 and 2016 surveys was based on the 1996 census, whereas for the surveys conducted since 2017, 
population data from the 2014 census were used. The earlier census did not reflect the increased population in mining 
areas. The apparent decrease in the percentage of children who received SMC in 2017 reflects a more representative 
sampling frame for the selection of survey villages, which included mining areas in Siguiri where SMC has been most 
challenging. These areas were not included in the 2016 survey. 
   




Figure 1: A - Scale-up of SMC 2015-2018.  B- Population distribution in SMC areas 
 
A: Scaling up of SMC in Guinea 
 
B: Spatial distribution of population in SMC areas  
Source for spatial population data: Worldpop (2019) 
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SMC target population in 2019 
The total estimated population of children to be treated was 818,503 (Table 5). The 2014 
census estimates of the population were used for probability proportional to size selection 
of survey clusters and for calculation of survey weights.  
 









Clusters 2014 Census  
population 
Siguiri 157,639 19.3% 179,333 11 708,506 
Kankan 109,713 13.4% 105,578 15 963,264 
Mandiana 78,161 9.5% 77,431 5 335,921 
Labe 76,221 9.3% 73,786 5 318,938 
Mali 70,937 8.7% 68,741 5 290,614 
Kouroussa 62,446 7.6% 64,442 8 545,212 
Gaoual 47,103 5.8% 45,819 3 196,190 
Dinguiraye 46,804 5.7% 45,797 4 199,465 
Lelouma 43,473 5.3% 42,084 2 163,069 
Dabola 42,142 5.1% 41,734 3 181,129 
Koundara 31,184 3.8% 30,335 2 131,388 
Tougue 29,468 3.6% 28,484 2 125,405 
Koubia 23,212 2.8% 22,430 1 101,293 
TOTAL 818,503  825,994 66 4,260,394 
 
  




The survey was conducted from 20 Dec 2019 to 4 Jan 2020 in 13 prefectures. Sixty-six 
settlements were selected from 13 prefectures where SMC was implemented in 2018 in the 
country (Figure 2), with probability proportional to population size based on the 2014 
General Population and Housing Census (RGPH), and in each selected settlement, in order to 
minimise selection bias, area sampling was used, whereby the settlement was divided into 
segments, one segment chosen at random, and all households in the selected segment 
included in the survey. Data were collected on tablet PCs which automatically selected the 
segment and recorded the GPS location of each dwelling visited. In each household, 
caregivers of children were asked about SMC treatments their child had received, and SMC 
record cards were inspected and photographed. All children aged 3 months to 7 years were 
included in order to determine coverage in the target age group (aged at least 3months at 
the time of treatment, and aged not more than 59 months at cycle1) and to determine the 
proportion of children just above the recommended age limit who received treatment. In 
addition, all persons who slept in the household the night before the survey were listed, all 
bednets owned by the household were also listed and inspected, and for each person, the 
net they slept under, if any, was noted.  
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Figure 2: Location of SMC Coverage survey clusters.  
(Note there are 66 clusters: Siguiri 11, Kankan 15, Mandiana 5, Labe 5, Mali 5, 
Kouroussa 8, Gaoual 3, Dinguiraye 4, Lelouma 2, Dabola 3, Koundara 2, Tougue 2, Koubia 1). 
 
Training, piloting and data collection 
Training took place over 2 days, 17-18 Dec 2019. The training covered the use of the survey 
tools, understanding the questionnaires, and field methods. 30 participants participated in 
the training: 18 interviewers, 2 NMCP staff, 5 supervisors, 3 substitute interviewers, and 2 
trainers. The first day covered operation of tablet PCs, tablet settings, and the use of the 
data entry software, and comprehension and practice in the use of the data entry forms. 
The second day covered taking photographs of SMC cards, recording GPS coordinates, 
saving and finalizing a form, making corrections and field methods. Data collection was then 
piloted in the field on Dec 19, 2019, teams were trained in identifying segments of the 
survey villages, and administration of survey questionnaires. For the main survey, which 
started Dec 20 and ended on 4 Jan 2020, survey staff were organised in 6 teams. 
 
Data management 
Data were collected using Android tablets (Nexus 7 (4 devices) and Samsung T285 Galaxy 
Tab A (17 devices)).  Software used was ODK.  The ODK form metadata are available from 
the authors.  The form used nested repeat structures to enable the capture of data at the 
household, caregiver and child levels – with linkage between the levels implemented 
directly through the ODK tool. The ODK aggregate server was based at the London School of 
Hygiene and Tropical Medicine.  The devices used strong encryption so that if devices were 
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lost the data could not be seen by non-team members.  Encryption was also used on the 
aggregate server, and the only way to retrieve the meaningful data was by using suitably 
setup ODK Briefcase – which allowed the decryption of the data from the server.  The data 
were delivered as CSV files (in UTF 8 format).  These files were then inserted into 
spreadsheet workbooks (separate sheet for each level).  These spreadsheets were made 
available to members of LSHTM team and the data manager based in Guinea so that the 
data could be reviewed (for cleaning purposes) and for analysis. A separate MS Access 
version of the data sets was created, again using the source csv files, so that the images of 
the cards could also be reviewed against the data entered.  This was used to identify missing 
data from the cards. The MS Access database became the cleaned version of the database, 
and it was the source used for analysis.  The data were extracted from the Access database 
using MS PowerBI – which enabled the decoding of the data gathered into the meaningful 
labels (e.g. so Male and Female were generated, rather than 1 and 2), and the merging of 
the data from the different levels. All data sharing between teams was implemented using 
MyFiles – the secure sharing platform used by LSHTM. 
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Number of treatments administered in each cycle in 2019
Administrative data 
A total of almost 3 million treatments were administered in 2019 (2,986,364, of which 
454,030 (15.2%) to infants and 2,532,334 to children). The fourth cycle was not 
implemented in PMI areas. In most prefectures, the number of treatments administered per 
cycle was similar in each cycle. The variation was greatest (greater than 10% difference 
between the maximum and minimum per cycle) in Siguiri, Dabola and Kouroussa. 















Prefecture 1 2 3 4 Total % variation  
(max-min)/max 
Dinguiraye 46138 45774 46219 
  
0.96% 
Gaoual 45595 46654 46832 
  
2.64% 
Koubia 22090 22412 22773 
  
3.00% 
Koundara 29885 30915 31318 
  
4.58% 
Mali 68432 69243 69367 
  
1.35% 
Tougue 28222 29339 29432 
  
4.11% 
Labe 68425 73133 73689 
  
7.14% 
Lelouma 41976 43173 43029 
  
2.77% 
Siguiri 172590 183523 176172 164491 
 
10.37% 
Mandiana 84790 91278 89870 84705 
 
7.20% 
Dabola 39460 43100 44041 40497 
 
10.40% 
Kankan 110898 115207 112716 104300 
 
9.47% 
Kouroussa 60984 65661 68542 59474 
 
13.23% 
Total 819485 859412 854000 453467 2986364  
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Administrative data from SMC reports from the 2019 campaign provided by the PNLP, are 
summarised in Tables 7-14. Results are presented separately for PMI and GF areas as the 
number of cycles differed.  
Vomitting: Overall, 1.4% of infant treatments and 0.4% of treatments to children 12-59 
months, were vomited and a second dose administered. Infants were about 3 times more 
likely to vomit than older children. The risk of vomiting was highest in the first cycle, and 
lowest in the fourth cycle. 













Risk ratio (95%CI) 
(both ages  
combined) 
Risk ratio (95%CI) 
(infants:children) 
1 54446 1045 (1.92%)  296317 2041 (0.69%) 1 2.9 (2.4,3.3) 
2 56540 990 (1.75%) 304103 1570 (0.52%) 0.80 (0.68,0.94) 3.4 (2.8,4.0) 
3 56341 979 (1.74%) 306318 1558 (0.51%) 0.79 (0.66,0.95) 3.3 (2.9,3.8) 
TOTAL 167327 3014 (1.80%) 906738 5169 (0.57%)  3.2 (2.9,3.5) 
 











Risk ratio (95%CI) 
(both ages combined) 
Risk ratio (95%CI) 
(infants: children) 
1 70808 1146 (1.62%) 397914 2133 (0.54%) 1 3.0 (2.5,3.6) 
2 77759 879 (1.13%) 421010 1368 (0.32%) 0.64 (0.54,0.75) 3.5 (3.1,4.1) 
3 74821 819 (1.09%) 416520 1221 (0.29%) 0.59 (0.54,0.66) 3.7 (3.1,4.5) 
4 63315 667 (1.05%) 390152 832 (0.21%) 0.48 (0.40,0.58) 4.9 (4.1,5.8) 
TOTAL 286703 3511 (1.22%) 1625596 5554 (0.34%)  3.6 (3.2,4.0) 
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Referral: Referrals were relatively uncommon. Infants were twice as likely to be referred, 
due to illness, than older children (both zones combined: 0.34% compared to 0.15%, risk 
ratio 2.3, 95%CI 1.9,2.7). Referrals were more common during cycle 1 than other cycles.  
Table 9: % of children who were referred (PMI zone) 
 Infants 3-11 months Children 12-59 months   








Risk ratio (95%CI) 
 (both ages combined) 
Risk ratio (95%CI) 
(infants:children) 
1 56796 488 (0.86%) 300114 1102 (0.37%) 1 2.3 (1.7,3.2) 
2 58027 207 (0.36%) 306813 613 (0.20%) 0.50 (0.35,0.73) 1.8 (1.3,2.3) 
3 57456 208 (0.36%) 308447 465 (0.15%) 0.41 (0.28,0.62) 2.3 (1.6,3.3) 
TOTAL 172279 903 (0.52%) 915374 2180 (0.24%)  2.2 (1.8,2.7) 
 
Table 10: % of children who were referred (GF zone) 
 Infants 3-11 months Children 12-59 months   








Risk ratio (95%CI) 
 (both ages combined) 
Risk ratio (95%CI) 
(infant:children) 
1 72075 294 (0.41%) 401376 897 (0.22%) 1 1.9 (1.5,2.6) 
2 78564 135 (0.17%) 422724 262 (0.06%) 0.31 (0.18,0.54) 2.9 (1.9,4.3) 
3 75396 117 (0.16%) 417743 224 (0.05%) 0.27 (0.11,0.62) 2.7 (1.6,4.5) 
4 63755 116 (0.18%) 391151 186 (0.05%) 0.26 (0.09,0.77) 3.6 (2.2,5.7) 
TOTAL 289790 662 (0.23%) 1632994 1569 (0.10%)  2.4 (1.9,3.1) 
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Exclusions for reasons other than sickness: Children are excluded if they are outside the 
age range for SMC, or have a history of allergy to SMC drugs, or had taken sulfa-containing 
medicine or amodiaquine (apart from their last SMC) within the last 4 weeks. Infants were 
more likely to be excluded than children, and the number excluded was, as is expected, 
highest in cycle 1. In cycle 1, 3.2% of infants were excluded in the PMI zone and 1.3% in the 
GF zone.  
Table 11: % of children who were excluded (PMI zone) 
 Infants 3-11 months Children 12-59 months   








Risk ratio (95%CI) 
 (both ages combined) 
Risk ratio (95%CI) 
(infants:children) 
1 56796 1822 (3.21%) 300114 2615 (0.87%) 1 4.1 (3.3,5.0) 
2 58027 1259 (2.17%) 306813 2034 (0.66%) 0.72 (0.60,0.86) 3.5 (3.1,4.0) 
3 57456 906 (1.58%) 308447 1658 (0.54%) 0.56 (0.43,0.72) 3.0 (2.6,3.5) 
TOTAL 172279 3987 (2.31%) 915374 6307 (0.69%)  3.6 (3.2,4.1) 
 
Table 12: % of children who were excluded (GF zone) 









Risk ratio (95%CI) 
 (both ages combined) 
Risk ratio (95%CI) 
(infants:children) 
1 72075 962 (1.33%) 401376 2512 (0.63%) 1 2.2 (1.9,2.5) 
2 78564 668 (0.85%) 422724 1445 (0.34%) 0.57 (0.48,0.67) 2.6 (2.1,3.1) 
3 75396 458 (0.61%) 417743 999 (0.24%) 0.40 (0.35,0.45) 2.6 (1.9,3.5) 
4 63755 324 (0.51%) 391151 809 (0.21%) 0.34 (0.24,0.49) 2.4 (1.4,4.1) 
TOTAL 289790 2412 (0.83%) 1632994 5765 (0.35%)  2.4 (2.1,2.7) 
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Refusals: These may include children who would not take the medicine and children whose 
caregiver refused for them to have SMC. There were 288 refusals out of 3,010,437 children 
seen (about 1 per 10,000). Most of these were in the first cycle.  
Table 13: % of children who refused (PMI zone) 
 Infants 3-11 months Children 12-59 months   








Risk ratio (95%CI) 
 (both ages combined) 
Risk ratio (95%CI) 
(infants:children) 
1 56796 40 (0.07%) 300114 80 (0.03%) 1 2.6 (1.4,5.0) 
2 58027 21 (0.04%) 306813 63 (0.02%) 0.68 (0.12,3.8) 1.8 (0.5,6.5) 
3 57456 1 (0.00%) 308447 6 (0.00%) 0.06 (0.01,0.36) 0.9 (0.3,2.5) 
TOTAL 172279 62 (0.04%) 915374 149 (0.02%)  2.2 (1.2,4.1) 
 
Table 14: % of children who refused (GF zone) 
 Infants 3-11 months Children 12-59 months   








Risk ratio (95%CI) 
 (both ages combined) 
Risk ratio (95%CI) 
(infants:children) 
1 72075 11 (0.02%) 401376 53 (0.01%) 1 1.2 (0.6,2.3) 
2 78564 2 (0.00%) 422724 7 (0.00%) 0.1 (0.0,0.5) 1.5 (0.3,6.8) 
3 75396 0 (0.00%) 417743 0 (0.00%) 0.0 (0.0,0.0) - 
4 63755 0 (0.0%) 391151 4 (0.00%) 0.1 (0.0,0.5) - 







Layout of the results 
Results for the key indicators are presented overall (average value for all 13 prefectures), and for 
each of four areas defined as follows:  
Area 1 - prefectures which started SMC in 2015 (Gaoual, Koundara, Koubia, Mali, Dinguiraye, 
Tougué);  
Area 2 – prefectures which started SMC in 2016 (Mandiana and Siguiri)  
Area 3 – prefectures which started SMC in 2017 (Labé, Lelouma) 
Area 4 – prefectures which started SMC in 2018 (Dabola, Kouroussa, Kankan) 
 
Areas 1 and 3 are supported by PMI and Areas 2 and 4, Global Fund. In 2019, the fourth cycle 
was not implemented in PMI areas, therefore in this report for some analyses, results  are 
presented grouping together areas 1 and 3 (PMI) and areas 2 and 4 (Global Fund, GF). 
 
Estimates for each prefecture separately are also provided but for some prefectures the number 
of clusters is small and the survey is not designed to produce reliable estimates in these 
prefectures. 
 
95% confidence intervals are presented for the key indicators which show the degree of 






A total of 1,038 households participated in the survey (Table 15), 89% of all households visited. 
The location of the clusters is shown in Figure 2. A total of 2536 children were included, of these 
1893 were aged 3-59 months at the time of cycle 1 and hence eligible to have received four SMC 
treatments. 244 children were aged 6-7 years when the survey was done and so were above 5 
years of age at the time of SMC cycle 1. 
 
Table 15: Response rates and the number of households, children and other household 
members surveyed: 
Households surveyed: No. of households %  
Agreed to participate 1038 89.2% 
No children of eligible age      82   7.0% 
Refused to participate        0   0.0% 
Unable to find someone to speak with/no access      44   3.8% 
TOTAL 1164   
Children surveyed: No. of children  
Aged 3-59 months at cycle 1 (eligible for 4 SMC treatments) 1893  
Aged 5-6 years at survey   252  
Aged 6-7 years at survey (more than 5 years of age at cycle 1)   244  
Aged <3months at cycle 1   147  
TOTAL (3 months to 7 years at survey) 2536  
Aged at least 3 months at cycle 4 and <5yrs (eligible at C4) 2040  
Caregivers surveyed:   868  





Timing of SMC cycles 
SMC treatments provide a high degree of protection for 28 days, after this time protection 
decreases rapidly. SMC cycles should therefore take place at intervals of 28 days (the first day of 
the cycle starting 28 days after the first day of the previous cycle), to ensure children remain 
protected. Cycle 1 took place in July, cycle 2 in August, cycle 3 in September and cycle 4 in 
October (Figure 4). The median interval between treatments, based on dates recorded on SMC 
cards, in PMI areas was 35 days between cycle 1 and cycle 2, and 31 days between cycle 2 and 3, 
and in GF areas, 33 days between cycle 1 and 2, 32 days between cycle 2 and 3, and 33 days 
between cycles 3 and 4. These intervals should be reduced to 28 days. Cases will increase in the 
5th week as protection wanes rapidly after 4 weeks. 
 
Table 16: Planned timing of cycles:  
1 2 3 4 
GF zone (Areas 2 and 4) 16 Jul-20 Jul 18 Aug-22 Aug 20 Sep-24 Sep 22 Oct-26 Oct 
PM zone (Areas 1 and 3) 13 Jul-17 Jul 17 Aug-21 Aug 17 Sep-21 Sep 
 
 
Table 17: Median interval between treatments (min-max), in days, determined from dates 
SMC record cards  
GF PMI 
Cycle 1 to cycle 2 33 (23-37) 35 (29-37) 
Cycle 2 to cycle 3 32 (27-39) 31 (28-37) 






Figure 4: Interval between cycles 





























































Retention of SMC cards 
Of 1893 children eligible for 4 SMC treatments who were surveyed, 12% did not receive an SMC 
card (compared to 9% in 2018), 88% received an SMC card (91% in 2018).  Of those who received 
a card, 76% retained the card (compared to 69% in 2018). A total of 68% (1294) had a card 
available for inspection in the survey. 
 
Agreement between caregiver recall, the SMC card, and registers 
To assess the reliability of SMC status determined during the survey, the number of SMC 
treatments reported by the caregiver was compared with the number recorded on the SMC card 
(for those children who had a card for inspection in the survey), and, for a subset of children, the 
number recorded in the SMC register. Caregivers were asked about the number of treatments, 
before looking at the SMC card or register. Out of the 1893 children in the survey who were 
eligible for four treatments, a total of 1294 children had a card for inspection in the survey. In 55 
clusters where SMC registers were available, an attempt was made to find entries in the SMC 
register for the children in the survey who did not have an SMC card, and for some who did have 
a card. This was possible for 339/580 (58%) children without a card. The survey estimate, based 
on caregiver recall, of the percentage of children who received SMC at least once, among those 
who did not have a card available for inspection at the survey, was 56%. Therefore the number 
found in registers is what we would have expected, bearing in mind that most children who did 
not receive SMC are not included in registers. Register entries were also found for some children 
who had an SMC card (264/1064, 25%) although this was not done for all children with a card. 
  
Card No card Total 
Eligible for 4 treatments 1294 599 1893 
Register available 1064 580 1644 
Found in register 264 339 603 
 
In method comparison studies, two measures of the degree of agreement are commonly used, 
the percentage agreement, (the percentage of children for whom the methods of assessing SMC 
status agree), and the kappa statistic. The kappa statistic is an index of agreement which allows 
for there being a degree of agreement due to chance, and is relevant when there may be an 
element of guesswork - for example if caregivers did not know the number of treatments and 
guessed - there will be then be some agreement with the card or register, just by chance. 
Percentage agreement of 80% or more, and a kappa value of 0.6 or more, is generally considered 
to be an acceptable level of agreement between methods (McHugh 2012).  
 
None of the methods used in our survey is perfect, registers and cards may not always be 
completed, there could be a tendency to complete registers before children have been treated, 
and there could be errors such as completing the card for a different child, or the entering 
treatment in the wrong line in the register. Caregivers may be expected to know if their child has 
been treated at all this year, and whether the child was treated in the last cycle before the 
survey, but they might be expected to recall less reliably the number of times the child was 
treated this year, and least reliably, whether the child was treated in each of the four months. 
We do not have a gold standard, but we seek to show there is good agreement between 
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methods to justify their use. We are primarily interested in the number of treatments received 
by a child; the coverage in individual cycles is also important but is of secondary interest.   
 
The percentage agreement between caregiver’s recall and SMC record card, with regard to the 
number of treatments, for the 1,294 children with a card, was 83% (95% confidence interval 0.80 
to 0.85), with a kappa value of 0.73 (95%CI 0.69 to 0.76), indicating an acceptable level of 
agreement.  
Table 18: Agreement between recall and card, for children in the survey with an SMC record 
card:  
Number of treatments on the SMC card 
 
 






      
0 1 15 3 18 61 98 
1 0 41 0 2 0 43 
2 0 13 55 8 0 76 
3 0 13 15 436 13 477 
4 0 15 25 25 535 600        
Total 1 97 98 489 609 1,294 
 
For those children who did not have an SMC record card, agreement between caregiver’s recall 
and the register, in the 339 children who could be found in registers, was 79% (95%CI 74% to 
83%), with a kappa value of 0.64 (95%CI 0.56 to 0.71), again indicating an acceptable level of 
agreement. 
Table 19: Agreement between recall and register, for children without an SMC record card: 
 
Number of treatments in the SMC register 
 
 
0 1 2 3 4 Total 




      
0 
 
0 3 8 41 52 
1 
 
1 0 0 2 3 
2 
 
1 8 2 1 12 
3 
 
0 3 89 4 96 
4 
 
1 1 4 170 176        
Total 
 




Children who did not receive SMC at all, will not be listed in registers (except those few who 
were seen by the CHW, entered in the register, but did not get SMC). Out of the 580 children in 
clusters where a register was available, who did not have a card, 339 (58%) were found in the 
register and 241 (42%) were not found in the register. Of the 241 who were not found, 72% 
(173/241) did not receive SMC according to the caregiver, compared to 15% (52/339) of those 
who were found in the register.  
 
For those that had a card and were found in the register, agreement between the card and 
register was less good, there was 56% agreement (95%CI 50% to 62%), and a kappa of 0.38 
(95%CI 0.31 to 0.44). Where there was disagreement, there tended to be more treatments in the 
register than on the card, suggesting that CHWs may not always record treatments on the card. 
There were few cases where treatments were recorded on the card but not in the register. 
However, the survey team did not attempt to find register entries for every child who had a card 
so these data may not be representative. 
Table 20: Agreement between card and register: 
 
Number of treatments in the SMC register 
 
 
0 1 2 3 4 Total 
Number of  
treatments  
according  
to SMC card 
      
0 0 0 0 0 1 1 
1 1 16 4 8 26 55 
2 0 1 12 8 30 51 
3 0 0 3 35 33 71 
4 0 0 0 1 85 86       
 
Total 1 17 19 52 175 264 
 
Taken together, these results suggest we should combine the information from the card and 
caregiver recall, considering the child to have been treated when a treatment is recorded on the 
card, and when the caregiver reports the child was treated even if no treatment is marked on 
the card. Applying this rule to the 603 children found in registers, led to 77% agreement and a 
kappa of 0.61. In contrast, recall alone on the same 603 children gave 75% agreement with 
registers and a kappa value of 0.58. Caregivers appear to be able to recall the number of 
treatments quite reliably. 
 
The results also suggest that finding register entries for children who did not have a card, was 
successful. Allowing for the fact that most children who did not receive any SMC treatments will 
not be listed in the register, it appears that a high proportion of children who received SMC but 
did not have a card at the survey, were located in registers. We therefore recommend that 
registers be used in futures surveys to cross-check SMC status, for children who do not have a 
card, and for children who have a card. Registers are of course useful during SMC distribution, as 
having a list of children to be treated helps the community health worker ensure that children 
seen at one cycle are not missed in subsequent cycles, but they also serve a purpose for verifying 




The SMC card is a record and reminder for the caregiver, so it is important that it is completed. 
Caregivers may use the card to check if their child’s treatments are complete, they could then 
seek treatment at the health centre if they missed the door-to-door campaign. Training of CHWs 
should emphasise the importance of recording treatments on the SMC card as well as in the 
register, and the need to remind caregivers to use and retain the card.  
 
When caregivers reported more SMC treatments than were recorded on the SMC card, it is 
plausible that treatments were received but not recorded on the card by the community health 
worker, or that caregivers did not accurately recall the exact number of treatments. In the cases 
where the caregiver said the child had not received any SMC, but there were several SMC 
treatments recorded on the card, it is possible that the respondent was not the same person 
that cared for the child during the SMC campaigns, or that cards for different children had been 
swapped during SMC delivery. Overall, there was a high level of agreement between recall and 
card, as has been observed in previous surveys.  
 
In most of the cases where there was disagreement between combined card and caregiver 
recall, and the register, the number of treatments was greater according to the register, that is, 
there were more treatments in the register than according to either the card or the caregiver. 
This could occur if health workers enter treatments in the register before children have been 
treated, but we have no independent evidence of this happening. There could also be linkage 
errors, the wrong record in the register being used.  
 
In this report, we have used a combination of recall and card; the child was assumed to have 
been treated in a particular month if there was a treatment recorded on the card (even if the 
caregiver disagreed); if the caregiver stated the child had been treated, but there was no record 











Awareness about the SMC campaign 
Caregivers should be to be aware of the purpose of the SMC programme and need to know the 
day when SMC will be distributed in their area in order to ensure they are available on that day. 
The survey asked one caregiver in each household if the household was aware about SMC and, 
for the most recent cycle (cycle 4 in GF areas and cycle 3 in PMI areas) if they knew in advance 
the date the health workers would come. Overall, 94.7% of households were aware of the SMC 
campaign and 92.4% said they knew in advance the date of the campaign.  
 
Table 21: Public awareness about SMC: the percentage of households that were aware of the 
SMC programme, and the percentage that heard the last campaign date in advance. 
 
Area % households aware 
of SMC (95%CI) 
% households who 
heard date of last cycle 
in advance (95%CI) 
Dinguiraye, Gaoual, Koubia,  





Labe, Lelouma 99.4% (95.6%,99.9%) 100.0% (95.8%,100.0%) 
Siguiri, Mandiana 88.3% (68.6%,96.3%) 80.5% (62.3%,91.2%) 
Dabola, Kankan, Kouroussa 99.4% (97.7%,99.8%) 99.5% (97.7%,99.9%) 




The most common sources of information about campaign dates were health workers, friends 
and neighbours, criers, the radio, and the mosque or church (Table 22). In Siguiri, households 
were less likely to have heard from the health worker. Radio messages reached about 40% of 
households. 
 

























Dinguiraye, Gaoual, Koubia,  

















Labe, Lelouma 80.6% 39.4% 46.3% 0.0% 27.0% 1.0% 7.4% 0.0% 
Siguiri, Mandiana 32.1% 39.8% 81.0% 0.0% 33.4% 0.4% 75.9% 0.4% 
Dabola, Kankan, Kouroussa 92.0% 66.4% 51.2% 3.5% 37.6% 1.9% 78.6% 4.5% 





Characteristics of caregivers   
The caregiver was usually the child’s mother. 27% of caregivers looked after one child under the 
age of 5 years, 37% two children under 5, and 35% three or more children under 5. When asked 
how long they had been resident in the area, almost all (>99%) said they had lived there for at 
least 6 months. Only 43% of caregivers had had any formal (or Koranic) education.  
Table 23: Characteristics of caregivers 
Characteristic Categories % 
Age <18yrs 2.0%  
18-24yrs 22.5%  
25-34yrs 47.1%  
35-44yrs 22.7%  
45+yrs 5.8% 
Gender Male 1.4%  
Female 98.7% 
Relationship to child Parent 92.9%  
Sister/Brother 0.3%  
Aunt/Uncle 0.1%  
Grandparent 6.6%  
Neighbour 0.1%  
Other 0.1% 
Resident <6months 0.3%  
6months+ 99.7% 
No. of children <5yrs in their care 0 0.8%  
1 27.4%  
2 36.6%  
3 22.6%  
4 8.3%  
5 3.1%  
6 0.9%  
7 0.3% 
Any education None 57.0%  
Any formal/Koranic education 43.0% 
Years of education None 56.9%  
1-5yrs 31.8%  
6-10yrs 8.0%  
11+yrs 3.3% 
Marital status Unmarried 0.9%  
Married 97.3%  





Caregivers’ knowledge about SMC  
Caregivers were asked if they understood key aspects of SMC, they scored 70% overall on a 10-
point questionnaire. Most caregivers (84%) knew that SMC is used to prevent malaria and most 
(81%) knew that there are 2 tablets to be taken on the first day and one on each of the next two 
days (84%). However there was a widespread view that SMC drugs could be used for treatment if 
there was someone unwell in the household (only 44% of caregivers gave the correct response, 
that SMC drugs should not be used in this way), and only 62% of caregivers (62%) appreciated 
the importance of completing the 3-day course of treatment.  
Table 24: Caregivers’ knowledge about SMC:  
Question Correct 
response 
1 For how many months should the child take SMC 4 
2 SMC is given to prevent malaria Yes 
3 SMC can prevent other diseases No 
4 How many tablets should the child take on the first day? 2 
5 How many tablets should the child take on the second day? 1 
6 How many tablets should the child take on the third day? 1 
7 The child should swallow all the medication Yes 
8 I can give the tablets to someone else who is unwell No 
9 The child should complete the 3-day course of treatment Yes 
10 I should take the child to the health centre if unwell after SMC Yes 
Maximum score: 10 
 
Table 25: Caregivers’ knowledge scores on SMC and adherence to guidelines by CHW: 
Area 
Average caregiver  
knowledge score  
(out of 10) (95%CI) 
Average CHW score  
for adherence to  
guidelines (out of 8) (95%CI) 
Dinguiraye, Gaoual, Koubia, 
Koundara, Mali, Tougue 7.4 (6.5,8.4) 7.1 (6.4,7.7) 
Siguiri, Mandiana 5.6 (3.7,7.5) 7.9 (7.8,8.0) 
Labe, Lelouma 7.0 (6.2,7.9) 7.9 (7.9,8.0) 
Dabola, Kankan, Kouroussa 7.5 (7.0,7.9) 7.6 (7.2,8.0) 






Table 26a: Caregiver knowledge, % correct answers to each question 
 % correct 
Question 2018 2019 
For how many months should the child take SMC (4) 59.9% 61.1% 
SMC is given to prevent malaria  82.0% 83.5% 
SMC can prevent other diseases (correct answer No) 68.9% 70.2% 
How many tablets should the child take on the first day? (2) 79.4% 80.9% 
How many tablets should the child take on the second day? (1) 82.8% 84.3% 
How many tablets should the child take on the third day? (1) 82.8% 84.3% 
The child should swallow all the medication (Yes) 67.7% 68.9% 
I can give the tablets to someone else who is unwell (No) 43.7% 44.4% 
The child should complete the 3-day course of treatment  60.9% 61.7% 
I should take the child to the health centre if unwell after SMC 62.3% 63.4% 
 
 














For how many months should the child take SMC 59% 56% 39% 86% 
SMC is given to prevent malaria 79% 61% 88% 97% 
SMC can prevent other diseases 75% 57% 76% 68% 
How many tablets should the child take on the first day? 81% 61% 77% 95% 
                                                                    on the second day? 82% 61% 88% 97% 
                                                                        on the third day? 82% 61% 88% 97% 
The child should swallow all the medication 76% 59% 58% 78% 
I can give the tablets to someone else who is unwell 60% 36% 52% 28% 
The child should complete the 3-day course of treatment 73% 54% 73% 46% 
I should take child to the health centre if unwell after SMC 76% 57% 65% 55% 
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Community Health Worker adherence to SMC guidelines, as reported by 
caregivers 
CHW’s should check the child’s age, and before administering the treatment should ask about 
illness and refer the child if they are unwell, and should check the child has not had severe side 
effects to SMC before. They are also trained to explain to the caregiver how to administer the 
amodiaquine tablets on the next two days, and to advise caregivers about potential side effects 
and to bring the child to a health worker if they are become unwell after SMC. Caregivers of 
children who had received SMC, reported that the CHW generally followed these guidelines 
correctly and the scores were notably better than when the same questions were asked after the 
2018 campaign.  
 
Table 27: CHW adherence to guidelines 
 
Action % of caregivers who 
reported that the CHW 
performed the action at 
the last visit: 
  2017 2018 2019 
1 Check the child's age 100.0% 80.1% 99.7% 
2 Explain how to administer tablets 99.6% 79.8% 99.6% 
3 Check for illness or fever 98.9% 79.6% 99.1% 
4 Explain the common side effects of SMC drugs 97.0% 75.7% 94.7% 
5 Advise to bring the child to the health centre if they are unwell 97.0% 77.5% 96.6% 
6 Ask if the child had taken other medicines in the last 4 weeks 95.8% 71.1% 89.2% 
7 Ask if the child had side effects to SMC before 92.9% 70.1% 88.1% 









































Check the child's age 99.7% 99.0% 100.0% 100.0% 100.0% 
Explain how to administer tablets 99.6% 99.5% 100.0% 99.1% 99.8% 
Check for illness or fever 99.1% 97.7% 98.7% 100.0% 99.8% 
Explain the common side effects of SMC drugs 94.7% 89.6% 98.9% 99.2% 94.1% 
Advise to bring the child to the health centre if they are unwell 96.6% 95.0% 99.0% 96.3% 97.1% 
Ask if the child had taken other medicines in the last 4 weeks 89.2% 77.8% 100.0% 100.0% 86.4% 
Ask if the child had side effects to SMC before 88.1% 73.1% 98.7% 100.0% 87.5% 




SMC administration at the last cycle before the survey (cycle 4) 
Caregiver’s recall is likely to be most accurate about the last SMC treatment, so questions about 
administration of SMC drugs were asked specifically about SMC treatment at the fourth cycle 
(reported for GF areas only).  
 
In 97% of treated children, the first dose was directly observed (administered by the CHW 
(96.9%) or by the caregiver in the presence of the CHW (0.4%)). A small number of children 
(0.1%) received the first dose from the caregiver later, not observed by the CHW; the reason 
given was that the child was away at the time the CHW visited. And for 2.6% of children, the 
caregiver received the blister pack but did not administer the first dose. 
 
Table 29: Percentage of SMC treatments directly observed (cycle 4) 
Area % of treatments with  
first dose directly  
observed (DoT) 
Siguiri, Mandiana 99.5% (98.1%,99.9%) 
Dabola, Kankan, Kouroussa 95.3% (88.5%,98.1%) 
TOTAL 96.9% (92.7%,98.7%) 
 
Table 30:Administration of the first daily dose of cycle 4 
Administration of the first dose of Cycle 4 % of children 
By the CHW 96.9% 
By caregiver, observed by CHW 0.4% 
By caregiver, unobserved 0.1% 
By caregiver, but not done 2.6% 
 
The most common reason for not receiving SMC at cycle 4 were the caregiver was working in the 






Reported adherence to the unsupervised doses of amodiaquine was very high. Of eligible 
children treated at cycle 4, caregivers reported that 96.1% received all three daily doses.  
 
Caregivers were asked if the child swallowed all the medicine, spat out some medicine, or 
vomitted all the medicine. Most responded the child swallowed the medicine without vomitting.  
Of those who were treated, a total of 93.9% of children were reported to have received and 
swallowed the 3 daily doses without vomitting. 
 
The most common reasons for not receiving SMC at cycle 4 were that the health worker did not 
visit, or the caregiver was away in the fields or mines.  
 
Table 31: Reasons for missed treatments 
Reason % 
The health worker did not visit the household 58.9% 
Child was away at the time 26.5% 
Child was living away from home 7.3% 
Caregiver not available 2.5% 
Child was unwell 1.5% 
Family refused 1.5% 
Other reasons 0.9% 
Child has history of allergies to drugs 0.6% 





Caregivers’ comments of the SMC programme 
Caregivers were asked for suggestions to improve the SMC programme. There were 178 
responses, the points most commonly made were to include older age groups, provide new 
health facilities, improve accessibility of remote areas, increase the quantity of SMC drugs, 
increase the number of months of SMC, provide SMC in the mines, and provide more bednets. 
Table 32: Caregivers’ comments on the SMC programme 
Comment % 
Include older age groups (older children, adults) 40.4% 
Build health centre/hospital/health post 7.9% 
Improve road access 7.3% 
Increase quantity of SMC drugs 6.7% 
Increase number of monthly cycles 5.1% 
Deliver in the fields 3.9% 
Bring bednets 3.9% 
Increase number of SMC cards 3.9% 
Include pregnant women 3.9% 
Increase number of days each month 3.4% 
Deliver in the mines, to reach those staying in mining 
areas 
1.7% 
Improve pay and conditions of health workers 1.7% 
Increase number of drug distributors 1.7% 
Provide information in good time 1.7% 
Improve health provision generally 1.1% 
Include all prefectures in Guinea 1.1% 
Provide a second opportunity to get SMC 0.6% 
Build a school 0.6% 
Improve training for drug distributors 0.6% 
Bring other medicines for children 0.6% 
Ensure enough registers 0.6% 
Cover transport costs or drug distributors 0.6% 
Provide financial assistance 0.6% 






Time taken to receive SMC  
SMC delivered door-to-door involves few costs to the household but someone responsible has to 
be available when the CHW visits and this may interfere with other activities. 94% of households 
reported that the mother was with the child during the CHW visit (Table 33). About 50% of 
households reported that they waited less than one hour for the CHW to visit, 24% more than an 
hour, but about a quarter could not say how long they waited (Table 34).  
 
Table 33: Household member who waited with the child for SMC 









Table 34: Amount of time spent waiting  for SMC 
Time spent waiting for the CHW % of households 
Less than 1 hour 50.1% 
1-2 hours 13.8% 
Up to half a day 6.4% 
A full day 1.8% 
More than 1 day 1.2% 





Total number of SMC treatments received by each child 
Children aged 3 to 59 months at the time of cycle 1 are eligible to receive SMC four times, and 
should receive all of these treatments to maximise their protection. The mean number of 
treatments per child was 2.9. Overall, 81% of children received SMC at cycle 1, 79% at cycle 2, 
78% at cycle 3 and 49% at cycle 4. Overall, 41% received four treatments. 58% received four 
treatments in GF areas.  
 
Cycle 4 was not implemented in PMI areas. However, there appeared to be some limited SMC 
distribution in some PMI areas, some children had cycle 4 treatment dates for 2019 marked on 
the SMC cards and in registers.  
 
Coverage was similar from month to month. As in previous years, coverage was poor in Siguiri 
(average monthly coverage 44%), and as this has the largest target population, this brings down 
the overall national figures of SMC coverage.  
 
Overall, 14.5% of children did not receive any SMC treatments, slightly less than in 2018 and 
2017 (21%). Most of the children who did not receive any SMC are in Siguiri where 48% of 
children did not receive SMC.  
 
SMC coverage in each year since 2015 is compared in Table 37. 
 
Table 35: SMC coverage among children eligible for four treatments, by area (with 95%CI) 





Cycle 1 Cycle 2 Cycle 3 Cycle 4 
Dinguiraye, Gaoual, Koubia, 









Labe, Lelouma 2.9 73.5% 98.3% 97.8% 96.8% 1.1% 
Dabola, Kankan, Kouroussa 3.3 83.7% 85.9% 85.0% 81.5% 82.4% 
Siguiri, Mandiana 2.2 54.2% 58.2% 52.0% 55.4% 51.3% 





Table 36: Coverage in each cycle, by prefecture 
Prefecture C1 C2 C3 C4 
Dabola 93.0% 99.3% 99.3% 93.7% 
Dinguiraye 100.0% 100.0% 100.0% 28.9% 
Gaoual 92.3% 88.7% 81.9% 0.0% 
Kankan 83.3% 79.8% 78.3% 78.5% 
Koubia 100.0% 100.0% 91.7% 8.3% 
Koundara 82.4% 79.9% 79.9% 0.0% 
Kouroussa 89.1% 91.1% 81.8% 86.7% 
Labe 98.6% 97.3% 96.1% 0.0% 
Lelouma 96.9% 100.0% 100.0% 6.1% 
Mali 94.5% 98.8% 98.8% 0.0% 
Mandiana 87.1% 83.6% 83.4% 82.5% 
Siguiri 48.8% 41.6% 46.3% 41.1% 
Tougue 100.0% 100.0% 100.0% 2.4% 
 
 
Table 37: Comparison of coverage with 2015 and 2016: mean number of treatments per child 
in each year 
Prefecture 2015 2016 2017 2018 2019 
Dinguiraye 3.25 3.65 3.99 3.82 3.29 
Gaoual 2.46 3.29 3.10 3.31 2.63 
Koubia 3.26 3.52 3.54 3.36 3.00 
Koundara 3.16 2.75 2.49 3.41 2.42 
Labé 
  
3.04 3.33 2.92 
Lelouma 
  
3.83 3.25 3.03 
Mali 3.20 3.40 2.97 3.80 2.92 
Mandiana 
 
3.46 3.49 3.85 3.37 
Siguiri 
 
3.48 2.12 1.43 1.78 
Tougé 3.50 3.89 3.79 3.58 3.02 
Dabola    3.30 3.85 
Kouroussa    3.67 3.49 
Kankan    3.29 3.20 

























































































(58.6%,80.8%)       











Table 39: Number of SMC treatments: percentage of children who received SMC 0,1,2,3,or 4 
times, by prefecture 
Prefecture 0 1 2 3 4 At least 1 
Dabola 0.0% 0.7% 0.0% 12.6% 86.7% 100.0% 
Dinguiraye 0.0% 0.0% 0.0% 71.1% 28.9% 100.0% 
Gaoual 7.7% 2.5% 8.9% 80.8% 0.0% 92.3% 
Kankan 10.7% 6.6% 5.4% 6.8% 70.5% 89.3% 
Koubia 0.0% 0.0% 8.3% 83.3% 8.3% 100.0% 
Koundara 17.6% 2.6% 0.0% 79.9% 0.0% 82.4% 
Kouroussa 1.6% 1.3% 9.4% 21.9% 65.8% 98.4% 
Labe 0.7% 0.6% 4.4% 94.2% 0.0% 99.3% 
Lelouma 0.0% 0.0% 3.1% 90.8% 6.1% 100.0% 
Mali 1.2% 0.0% 4.3% 94.5% 0.0% 98.8% 
Mandiana 0.0% 5.8% 10.7% 24.8% 58.8% 100.0% 
Siguiri 48.1% 6.1% 1.6% 8.3% 35.9% 51.9% 





Equitability of SMC coverage 
The proportion that received no SMC was lower in the poorest two wealth rankings and 
increased in the higher rankings (test for trend, P=0.002). There was no evidence that the 
coverage of four treatments was associated with wealth ranking (test for trend, P=0.584). SMC 
coverage was similar in boys and girls. 
 
Table 40: SMC treatment by wealth ranking 
SES Mean number of  
SMC treatments  
(95%CI) 
% that received  
four  SMC  
treatments 
% that received at  
least one SMC  
treatment 
% that received  
no SMC 
Lowest 2.9 (2.7,3.2) 28.0% (15.5%,45.1%) 92.3% (84.1%,96.5%) 7.7% (3.5%,15.9%) 
Low 3.3 (3.0,3.5) 56.9% (40.6%,71.8%) 93.6% (87.4%,96.8%) 6.4% (3.2%,12.6%) 
Middle 2.7 (2.4,3.1) 31.4% (18.4%,48.2%) 84.6% (69.8%,92.8%) 15.4% (7.2%,30.2%) 
High 2.6 (2.2,3.1) 37.6% (25.9%,50.9%) 79.6% (62.5%,90.1%) 20.4% (9.9%,37.5%) 
Highest 2.7 (2.4,3.1) 47.1% (35.6%,59.0%) 80.5% (70.1%,87.9%) 19.5% (12.1%,29.9%) 
 
Table 41: SMC treatment by gender 
Gender Mean number of  
SMC treatments 
% that received  
four  SMC  
treatments 
% that received at  
least one SMC  
treatment 
% that received  
no SMC 
Boys 2.8 (2.6,3.1) 39.4% (29.5%,50.2%) 85.2% (76.1%,91.2%) 14.8% (8.8%,23.9%) 






Treatment of children above the age of 5 
Children who are 5 years of age and above at the time of the first SMC cycle, should not receive 
SMC. The dose has been calculated according to age and if children above the age of 5 are given 
the blister pack intended for the 12-59-month group, they may be under-dosed, this can select 
for resistance as parasites are exposed to sub-therapeutic doses of SMC drugs. Children aged 
above 6 years at the time of the survey, should not have received SMC.  
 
244 children 6years and above were surveyed. 13.9% (95%CI 7.1%,25.6%) received an SMC card. 
13.0% received SMC at least once, 10.9% received SMC in cycle 1, 9.6% in cycle 2, 10.2% in cycle 
3 and 1.8% in cycle 4. The mean number of treatments was 0.32. 
 
It appears that treatment of older children has been reduced in 2018 (Table 25). In 2017, 53.8% 
of this group received an SMC card and about 40% received SMC at each cycle. In 2018, only 
17.5% received a card and about 15% received SMC at each cycle. In 2019, 14% received a card 




Table 42: Treatment of children above the age limit for SMC (aged 6-7 years at the survey) 
 
 
Treated at cycle: 
   
 
Year Mean number  
of treatments 




2017 1.68 42.8% 43.9% 43.5% 38.2% 53.8% 189 
2018 0.63 16.3% 16.5% 15.3% 14.9% 17.5% 327 





Comparison of administrative and survey estimates of SMC coverage  
Administrative estimates of coverage (the number treated as a percentage of the estimated 
target population), tend to over-estimate the percentage of eligible children who received SMC, 
partly because estimates of the target population often under-estimate the actual number, and 
partly because administrative data on the number of doses administered, include doses given to 
children outside the recommended age range. In surveys, interviewers check the age of each 
respondent and we limit estimates of coverage to children known to be aged at least 3 months 
and less than 60 months at the time of the first SMC cycle 1, (children eligible for 4 treatments), 
or to children aged less than 60 months at cycle 1 and aged at least 3 months at cycle 2, 3 or 4 
(eligible for SMC at that cycle). In our survey reports we generally limit analyses to the group of 
children eligible for 4 cycles, apart from analyses of adherence, which include children who were 
eligible at cycle 4. 











1 818502 819485 100.1% 81.0% 
2 818502 859412 105.0% 78.6% 
3 818502 854000 104.3% 77.9% 
4 818502 453467 55.4% 48.6% 
TOTAL 3274008 2986364 91.2% 71.5% 
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Bednet use by children  
Bednet use the night before the survey was recorded in the survey for children receiving SMC. 
Insecticide-treated bednets are the most cost-effective method of malaria prevention, SMC adds 
to this protection but does not replace the need to use bednets - ITNs or LLINs (long-lasting 
insecticide-treated nets).  
 
In the survey after the 2017 SMC campaign, 43.6% of children in the survey (children eligible to 
receive SMC) were reported to have slept under a bednet the night before the survey.  
 
In the 2018 survey, 30.2% of children slept under a net the night before the survey. The survey 
was conducted after the main malaria season and bednet use may be lower at this time than in 
the main season but nevertheless bednet use was surprisingly low. There were notable 
variations with very low use of nets in some prefectures. 
 
In this 2019 survey, 86% (95%CI 79%,90%) of children slept under an LLIN the night before the 
survey. 97% of the nets the children were using were less than 8 months old according to 
caregivers. 
Table 44: Percentage of children 3-59months who slept under a LLIN the night before the 
survey 
Area % slept under a  
LLIN last night (95%CI) 
Dinguiraye, Gaoual, Koubia, 
Koundara, Mali, Tougue 87.1% (78.8%,92.4%) 
Labe, Lelouma  92.3% (88.4%,95.0%) 
Siguiri, Mandiana 75.9% (56.9%,88.3%) 
Dabola, Kankan, Kouroussa 90.7% (86.4%,93.8%) 
TOTAL 85.7% (79.2%,90.4%) 
 
Table 45: Bednet (LLIN) use by prefecture 
Prefecture % children 3-59 months 
who slept under a LLIN 
the night before the survey 
Number of children 
surveyed 
Dabola 87.2% 104 
Dinguiraye 79.9% 138 
Gaoual 93.5% 78 
Kankan 93.9% 448 
Koubia 100.0% 12 
Koundara 95.5% 43 
Kouroussa 84.9% 294 
Labe 90.6% 106 
Lelouma 100.0% 30 
Mali 86.9% 80 
Mandiana 90.9% 186 
Siguiri 71.1% 336 




Bednet use by all household members 
A total of 5,051 household members were surveyed in 1038 households. A total of 4,906 slept in 
the household the night before the survey. Household size (slept in the household the night 
before) ranged from 1 to 13. (Note that the survey was limited to households that had at least 
one child under 7 years of age and aged at least 3 months). 




0-4yrs 2,083 41.2% 
5-9yrs 648 12.8% 
10-14yrs 176 3.5% 
15-19 155 3.1% 
20-24 248 4.9% 
25-29 386 7.6% 
30-34 315 6.2% 
35-39 364 7.2% 
≥40yrs 553 11.0% 
Age missing 123 2.4% 
TOTAL 5,051 100.0% 





Table 47: Household size: Number of households, by household size, in each wealth ranking. 
The largest households are in the highest wealth ranking. 
 Wealth ranking  
Number slept in  
the household  
the night before  
the survey Lowest Low Middle High Highest Total 
1 0 0 1 2 0 3 
2 12 5 13 6 2 38 
3 53 49 42 34 26 204 
4 56 81 62 66 73 338 
5 46 40 46 46 36 214 
6 16 21 19 20 24 100 
7 8 8 10 12 17 55 
8 2 10 3 9 10 34 
9 0 5 4 5 6 20 
10 0 0 6 4 8 18 
11 0 0 1 1 4 6 
12 0 1 1 2 2 6 
13 0 1 0 1 0 2 
Total 193 221 208 208 208 1038 
Mean household size 4.2 4.6 4.6 4.9 5.3 4.7 
 (1038 households consented and included members who slept in the household the night before the 
survey) 
Overall, 79.7% used a LLIN the night before the survey, compared to 28.7% in the 2018 survey. 
There was a notable dip in bednet use in children 5-14 years of age. This is of concern as children 
stop receiving SMC when they are 5 years old (if they are more than 59 months old at the time of 
cycle 1). It is therefore especially important that these children use an LLIN. 
Table 48: Bednet use by age group (% that used a net, the night before the survey) 
Age group Any net LLIN Intact net Net <2years old 
0-4 85.4% 85.4% 84.0% 83.8% 
5-9 66.7% 66.7% 64.1% 65.6% 
10-14 65.9% 66.6% 61.5% 63.5% 
15-19 80.0% 80.9% 77.3% 77.3% 
20-24 78.2% 78.2% 74.8% 76.2% 
25-29 81.5% 81.6% 80.4% 80.0% 
30-34 79.4% 79.4% 77.5% 77.0% 
35-39 82.2% 82.1% 80.8% 80.1% 
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Net use was lower in Siguiri/Mandiana than in other areas. Net use was slightly lower among 
males than females (difference 6.0% (2.6%,9.4%, P=0.001)), and was higher in the lower wealth 
rankings (test for trend P=0.094). 
Table 49: LLIN use by area  
% slept under a LLIN the  
night before the survey 
(95%CI) 
AreA:  
Dinguiraye, Gaoual, Koubia,  
Koundara, Mali, Tougue 
 
88.0% (81.7%,92.3%) 
Labe, Lelouma  89.0% (75.7%,95.5%) 
Siguiri, Mandiana 66.9% (49.6%,80.6%) 
Dabola, Kankan, Kouroussa 85.8% (81.8%,89.0%)   
Gender: 
 
Male 76.6% (67.9%,83.5%) 
Female 82.4% (74.9%,88.0%)   
Wealth ranking: 
Lowest 87.9% (81.8%,92.1%) 
Low  80.0% (72.0%,86.2%) 
Middle 79.1% (63.7%,89.1%) 
High 76.7% (63.5%,86.2%) 




Of 1038 households surveyed, 89.8% had at least one LLIN and 36.8% had one LLIN for every 2 
persons. This compares with 39.7% had at least one LLIN and 13.1% had one LLIN for every 2 
persons in the household, in 2018. 
 
Table 50: Access to a bednet: % of households with at least one net, and % of households with 
at least one net for every two people who slept in the household the night before the survey 
  % households (95% CI) 
At least one net per household 2019 89.8% (84.7%,94.8%) 
 2018 39.7% (29.8%,49.5%) 
At least one net for every two persons 2019 36.8% (30.6%,42.9%) 
 2018 13.1% (7.5%,18.7%) 
 
Access to a LLIN, the percentage of the population who could sleep under a LLIN if there were two people 
per net, was 25.4% in 2018. This has increased to 68.2% in the current survey. 
Table 51: Access to a LLIN. Percentage of the population who slept in the household the night 
before the survey, who could sleep under a net if two people slept under each net.  
(values in the main part of the table are row percentages). 
 
No. of nets (LLIN) in the household 
  
 
0 1 2 3 4 5 6 7 
  
Number who slept  
in the household  
the night before  
the survey 






% who could 
sleep under a 
net if 2/net 
1 0.0% 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1 100.0% 
2 15.7% 77.0% 7.8% 0.0% 0.0% 0.0% 0.0% 0.0% 38 84.3% 
3 5.8% 62.7% 27.1% 4.3% 0.3% 0.0% 0.0% 0.0% 204 73.4% 
4 8.2% 29.1% 57.0% 4.5% 1.2% 0.0% 0.0% 0.0% 338 77.2% 
5 10.2% 10.3% 62.9% 15.8% 0.5% 0.5% 0.0% 0.0% 214 71.1% 
6 10.2% 14.2% 49.4% 23.6% 2.6% 0.0% 0.0% 0.0% 100 63.9% 
7 7.9% 6.7% 28.8% 43.8% 12.8% 0.0% 0.0% 0.0% 55 68.7% 
8+ 24.7% 4.5% 16.1% 27.4% 18.7% 5.3% 2.6% 0.7% 86 51.1% 









Annex A: Sampling methods 
The primary outcomes to be assessed in the survey were the percentage of eligible children who received 
SMC in each cycle and the percentage of children who received SMC four times. Children aged 5-7 years 
were included in the survey to determine the extent of SMC treatment above the age limit. It was also 
planned to ask about adherence to SMC doses, and reasons for missed treatments, and (for all household 
members) the use of long-lasting insecticide-treated bednets (LLINs).   
To achieve reasonable geographical coverage of survey clusters, and to be able to estimate the 
percentage of children who received SMC in each cycle with a margin of error of +/- 6%, it was estimated 
that 66 clusters of about 20 children per cluster would be required. Clusters were selected with 
probability proportional to population size (PPS), so that more clusters would be chosen in prefectures 
with larger population. 66 clusters selected with PPS resulted in the following allocation of clusters by 
prefecture: 
Dabola 3, Kankan 15, Kouroussa 8 
2017 prefectures: Dinguiraye, 4; Mandiana, 5; Siguiri, 11; Gaoual, 3; Koubia, 1; Koundara, 2; Labe, 5;  
Lelouma, 2; Mali, 5; Tougue, 2 
TOTAL: 66 
 
Sample size calculation 
The margin of error on the survey estimates of SMC coverage, depends on the level of coverage, the 
number of children surveyed, the number of clusters, and the design effect. Children within the same 
cluster tend to be similar in terms of the number of SMC treatments they received, the design effect 
measures the effect of this on the precision of survey estimates of coverage. For a given total sample size, 
one obtains better precision by having more clusters and fewer children per cluster, but logistic 
constraints limit the number of clusters, due to travel time and cost, and also because to ensure sampling 
is not biased, care is needed in each cluster to map where the dwellings are, divide the map into 
segments, and then to ensure all dwellings in the selected segment are visited.  
 
If the coverage is 80%, the margin of error is expected to be +/- 100x{1.96x√(Deff)x√[0.8x(1-0.8)/(bxC)]} 
where C is the number of clusters, b the mean number of children surveyed in each cluster, and Deff is 
the design effect. The design effect itself depends on the average number of children surveyed in each 
cluster (b), and the ‘rate of homogeneity’ which is a measure of the degree of similarity among children in 
a cluster: Deff=1+(b-1)roh . From earlier surveys, the roh value for the percentage of children who 
received four treatments was 0.3 and for the coverage per cycle between 0.41 and 0.54. If we include 
b=10 children in each cluster, the design effect for the percentage receiving 4 treatments is 1+(10-
1)x0.3=3.7. If we have 66 clusters, the margin of error on a coverage of 80% will be: 1.96x√[3.7)x(0.8x(1-
0.8)/(10x66)]=+/-5.9%. If there are 20 children per cluster, the design effect increases to Deff=1+(20-
1)x0.3=6.7, but the margin of error is little changed: 1.96x√[6.7)x(0.8x(1-0.8)/(20x66)]=+/-5.6%. 
 
It was therefore planned that segments should be chosen to include about 10-15 eligible children and as 
before should also include children age 5-7yrs to be able to determine the extent of treatment of older 
children. Clusters with 20 children aged 3 months to 7 years would include about 15 children 3-59 months 
and 5 children 5-7yrs. This would give a total sample size of about 66x20=1320. 
 
Compact segment sampling was to be used as before but with segments chosen to include about 10-15 
eligible children.  The expected precision in the 10 districts that had SMC in 2017 would be about +/-9% 





The survey was conducted in the prefectures of Gaoual, Koundara, Mali, Lelouma, Labe, Koubia, Tougué, 
Dinguiraye, Siguiri and Mandiana, Dabola, Kouroussa and Kankan, which implemented SMC in 208 and 
2019.  Ten of these prefectures were surveyed in 2017, Gaoual, Koundara, Mali, Lelouma, Labe, Koubia, 
Tougué, Dinguiraye, Siguiri and Mandiana. The estimated total population size of these 10 prefectures 
was 2,570,789 based on the 2014 census. In 2017, a sampling interval of 2,570,789/40= 64269.725 was 
used to select 40 settlements with probability proportional to size, using systematic sampling from a list 
of all 9352 settlements in the 10 prefectures, after sorting by prefecture to give an implicit stratification. 
The same sampling interval was used to select communities in Dabola, Kouroussa and Kankan in 2018. 
The total population of thee three prefectures from the 2014 census was 1,689,605, and interval of 
64269.725 gives a sample of 26 settlements. Thus a total of 66 settlements were surveyed in 2018. The 
same settlements, and the same segments within the settlements, were surveyed in 2019. 
The segmentation process that was used in 2017 and 2018 was as follows. A rough sketch map of each 
selected settlement was made showing areas of habitation and local landmarks. Each map was then 
divided into segments of approximately equal size, the number of segments being chosen so that one 
segment would be expected to yield approximately the required number of children, based on the 
estimated total population size, while as far as possible taking advantages of local features to facilitate 
identification of segment boundaries on the ground. Children aged at least 3 months at SMC cycle 4 in 
October, (hence at least 6 months at the time of the survey, conducted the following January) and less 
than 7 years at the time of the survey, were eligible to be included. It was assumed that this age group 
represents about 20% of the total population. A total sample size of about 1320 children was required, 
i.e. 1320/66=20 children on average from each settlement. Each settlement was therefore divided into 
S=max(1,floor(Nix0.2/20)) segments, where Ni was the population from the 2014 census. The segments 
were numbered on the map and then the number of segments created was entered into a tablet PC 
which used simple random sampling to select a segment number to be surveyed.  
 
Every dwelling within the chosen segment was visited and every child who was aged at least 3 months at 
the last cycle and was less than 7 years at the time of the survey, who had stayed in the house the night 
before the survey, was included in the survey. The GPS location of each dwelling visited was automatically 
recorded by the tablet PC used to collect interview data. The number surveyed in each settlement 
therefore could vary but the average was expected to be about 20 if the population data were accurate. 
There were 17 settlements that were selected which were too large for segmentation to be practical, and 
there was no information available about sub-divisions of these segments that could be used to select a 
smaller area. For these settlements, the total area was estimated by taking GPS locations around the 
perimeter of the inhabited area. A single location was then chosen, by randomly generating an x and y 
coordinate within the settlement (this was done independently of the survey team and the location sent 
to them by email). Interviewers surveyed houses around this point, recording the GPS location of each 
dwelling, and continuing outwards, without missing any dwellings, until the required number of children 
(20) had been reached. In the final dwelling, all children eligible for the survey were included so the final 
sample size could exceed 20.  
 
The sampling probability is pi=66x(Ni/NT)xfi xRi, for individuals in settlement I, where Ni is the population 
of village i from the 2014 census and NT is the total population of the 13 prefectures and Ri is the 
response rate in cluster i. For the settlements that were segmented, fi= (1/Si), where Si is the number of 
segments. For the settlements which were too large to segment, fi=(ai/Ai), where ai is the sampled area in 
settlement i, and Ai is the total area of the settlement. This is a rough and ready way to estimate sampling 
probabilities, where it can be assumed population density is approximately uniform. It is sensitive to the 
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way the sampled polygon is defined. To calculate sampled areas for the 17 large settlements, we plotted 
the GPS locations of the surveyed dwellings onto aerial photos of the settlements in Google Earth, and 
defined a polygon that was midway between the convex hull of the sampled coordinates and the next 
adjacent dwellings outside the sampled area, in the photograph. The convex hull itself would 
underestimate the sampled area. Response rates were averaged over each prefecture. Because it was not 
possible to inspect sleeping places in some households, there are different response rates for SMC-
related questions and for the bednet questions, and hence different weightings.  
 
The sampling weight for each child (the number of children in the population that each child surveyed 
represents) was 1/pi. 
 
Standard errors of estimates of indicators were computed using linearized variance formulae for ratio 
estimators. For binary variables, confidence intervals for proportions were obtained after using a logit 










Sampled Sampling  Response  Response  Weights Weights 






MANDIANA Balandougouba Sidikila II Sidikila II Centre 3616 1 36     0.00156 0.981 0.972 654.8 661.4 
MANDIANA Dialakoro Samory Touré Samory TOURE 3794 2 37     0.00159 0.981 0.972 641.4 647.9 
MANDIANA Kinieran Mbalia Mbalia Centre 12710 3   1081830 89681 0.01632 0.981 0.972 62.4 63.1 
MANDIANA Koundian Koundian I Namafouada 131 4 1     0.00203 0.981 0.972 502.1 507.1 
MANDIANA Morodou Samakofara 
Samakofara 
Centre 
1199 5 11     0.00169 0.981 0.972 603.4 609.5 
GAOUAL Foulamory Tabadian Nyor Nyor 668 6 7     0.00148 0.934 0.983 723.9 688.3 
GAOUAL Koumbia Dara Bowé Dara Bowé Centre 1315 7 13     0.00157 0.934 0.983 682.9 649.3 
GAOUAL Malanta Kounsi Peguéty 247 8 2     0.00191 0.934 0.983 559.4 531.9 




Thiuopoutel 497 10 5     0.00154 0.950 1.000 683.6 649.4 
DINGUIRAYE Banora Boubèrè Boubèrè Centre 793 11 8     0.00154 1.000 0.917 651.2 710.4 




Tinkisso Souloukoufalan 257 13 3     0.00126 1.000 0.917 753.5 822.0 
DINGUIRAYE Selouma Selouma Centre Sakabari 557 14 6     0.00137 1.000 0.917 695.3 758.6 




Franwalia Centre 5807 16   995165 6300 0.00047 0.989 0.803 1776.2 2185.4 
SIGUIRI Kintinian Balato III Balato Centre III 6354 17   1259773 8171 0.00064 0.989 0.803 1584.4 1949.4 
SIGUIRI Kintinian Fatoya Fatoya Centre 11449 18   1713351 7131 0.00074 0.989 0.803 1370.3 1686.0 
SIGUIRI Malea Maléah Centre Maléah Centre 2245 19 22     0.00158 0.989 0.803 639.9 787.3 
SIGUIRI Niagassola Kignekourou Faraboloni 436 20 4     0.00157 0.989 0.803 599.1 737.1 
SIGUIRI Norassoba NanenTraoré 
Nanen Traoré 
Centre 
4362 21   1365449 29993 0.00148 0.989 0.803 681.5 838.5 
SIGUIRI Siguiri-centre Dankakoura 
Dankakoura 
Centre 
1734 22 17     0.00153 0.989 0.803 640.2 787.7 
SIGUIRI Siguiri-centre Saourou Saourou Centre 4372 23   384840 7614 0.00134 0.989 0.803 754.9 928.8 
SIGUIRI Siguiri-centre Sougoula Sougoula Centre 2362 24 21     0.00174 0.989 0.803 580.5 714.3 
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Dougouwoulen 334 26 3     0.00129 0.643 1.000 901.9 579.8 
MALI Donghol Sigon Dougaya Dioma Roundé 413 27 4     0.0016 0.985 0.969 634.8 645.0 
MALI Fougou Kansaghel Laami 121 28 1     0.00187 0.985 0.969 541.7 550.4 
MALI Madina Wora Pellissaré Donghol Doubhi 131 29 1     0.00203 0.985 0.969 500.3 508.4 
MALI Salambande Koya Koya Centre 139 30 1     0.00215 0.985 0.969 471.5 479.1 
MALI Yembereng Sinthiourou Diaguitarè 113 31 1     0.00175 0.985 0.969 580.0 589.4 
TOUGUE Konah Bourouwal Kounsen 234 32 2     0.00136 0.784 0.931 703.9 592.6 




Bassanya II 644 34 6     0.00123 0.843 0.886 713.1 679.0 
LABE Labé centre Daka II Secteur II 7182 35   802786 42257 0.00432 0.843 0.886 202.5 192.8 
LABE Labé centre Madina 
Dianyabhè 
Mosquée 
1525 36 15     0.00084 0.843 0.886 752.8 716.9 
LABE Noussy Kassangui Dow Kougue 16 37 1     0.00025 0.843 0.886 4783.7 4555.0 
LABE Tountouroun Tounny Gadha Thiolliwel 174 38 1     0.00236 0.843 0.886 439.9 418.9 
LELOUMA Lafou Bombi Bourou Yalaya 103 39 1     0.00117 0.800 1.000 783.4 626.7 
LELOUMA Sagale Bamikountou Gnekori 85 40 1     0.00119 0.800 1.000 949.3 759.4 
DABOLA Banko Dalado Daffela 192 41 1     0.00297 1.000 0.930 336.2 361.4 
DABOLA Dabola-centre Foundeng II Foula 1524 42 15     0.00157 1.000 0.930 635.3 683.0 
DABOLA Kindoye Kindoye II Fissanya 146 43 1     0.00218 1.000 0.930 442.1 475.3 
KANKAN Balandougou Koba Koba Centre 2044 44 20     0.00158 1.000 0.955 631.6 661.4 
KANKAN Bate-nafadji Djelibakoro Total 9282 45   1132450 6873 0.00087 1.000 0.955 1145.9 1199.9 
KANKAN Boula Kalafilila Total 3045 46 30     0.00157 1.000 0.955 636.0 665.9 
KANKAN Kankan-centre Aviation Total 8560 47   3568746 32063 0.00119 1.000 0.955 839.4 878.9 
KANKAN Kankan-centre Briqueterie Total 12168 48   2409247 26167 0.00205 1.000 0.955 488.4 511.5 
KANKAN Kankan-centre Farako I Total 6511 49   355552 6145 0.00174 1.000 0.955 573.6 600.7 
KANKAN Kankan-centre Hermakonon II Total 8824 50   399040 6716 0.0023 1.000 0.955 434.7 455.1 
KANKAN Kankan-centre Madina Secteur II 5860 51   1387773 29940 0.00196 1.000 0.955 510.6 534.7 
KANKAN Kankan-centre Salamaninda Secteur III 3519 52 35     0.00156 1.000 0.955 642.0 672.3 
KANKAN Kankan-centre Timbo Secteur II 846 53 8     0.00164 1.000 0.955 610.4 639.2 
KANKAN Koumban Koumban I Koumban I Centre 2080 54 20     0.00161 1.000 0.955 620.7 649.9 
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778 56 7     0.00172 1.000 0.955 580.8 608.2 
KANKAN Tinti-Oulen Gbanankoura Total 2435 57 24     0.00157 1.000 0.955 636.2 666.2 
KANKAN Tokounou Sansambaya 
Sansambaya 
Centre 
1085 58 10     0.00168 1.000 0.955 594.9 623.0 
KOUROUSSA Balato Balato Centre Fodedou 390 59 3     0.00201 0.994 0.938 499.4 529.7 
KOUROUSSA Banfele Nafadji Total 4492 60   129739 9799 0.00526 0.994 0.938 191.3 202.9 
KOUROUSSA Cissela Fadoussaba Total 10985 61   604702 35272 0.00993 0.994 0.938 101.3 107.5 
KOUROUSSA Cissela Sonokoro Total 2578 62 25     0.0016 0.994 0.938 629.5 667.7 
KOUROUSSA Doura Farakoba Farakoba Centre 1728 63 17     0.00157 0.994 0.938 638.7 677.4 








Wassabada Secteur II (Raiko) 9031 66   740557 33152 0.00626 0.994 0.938 160.6 170.3 
*Some households did not participate (a respondent could not be found, or they refused); for some which responded, it was not possible to inspect 
sleeping places; thus there are separate response rates for SMC-related indicator and bednets, and hence different weightings. 
Total implied population at time of survey, aged 3-59 months, based on survey weightings:  1,218,748 
Total 2014 census population: 4,260,394  




Table A2: Standard error, design effect and rate of homogeneity for the main indicators 
Indicator N Value s.e. 95%CI Deff Deffweight Deffcluster roh b 
Average coverage per cycle 1893 0.715 0.0316 (0.65,0.78) 16.02 1.377 11.63 0.32 34.2 
Mean number of treatments per child 1893 2.86 0.1265 (2.61,3.11) 16.02 1.377 11.63 0.32 34.2 
Coverage of 4 cycles 1893 0.414 0.0509 (0.32,0.52) 20.20 1.352 14.94 0.42 34.2 
Adherence 1688 0.961 0.0101 (0.93,0.98) 4.53 0.988 4.59 0.12 31.3 
Reach of SMC programme 1893 0.855 0.0346 (0.77,0.91) 18.25 1.528 11.95 0.33 34.2 
Coverage of cycle 1 1893 0.810 0.0357 (0.73,0.87) 15.68 1.422 11.03 0.30 34.2 
Coverage of cycle 2 1893 0.786 0.0390 (0.70,0.85) 17.11 1.473 11.62 0.32 34.2 
Coverage of cycle 3 1893 0.779 0.0372 (0.70,0.84) 15.21 1.415 10.75 0.29 34.2 
Coverage of cycle 4 1893 0.486 0.0550 (0.38,0.59) 22.89 1.455 15.73 0.44 34.2 
Treatment of older children (treated at least once) 244 0.325 0.0433 (0.07,0.57) 4.31 2.119 2.04 0.04 24.5 
Awareness of SMC dates 1002 0.923 0.0248 (0.86,0.96) 8.67 1.698 5.11 0.23 19.0 
LLIN use in children 1881 0.857 0.0266 (0.79,0.90) 11.10 1.563 7.10 0.18 34.1 
LLIN use (all ages) 4897 0.796 0.0349 (0.72,0.86) 36.66 1.619 22.65 0.24 91.2 
ACCESS to LLIN (population) 4906 0.682 0.0308 (0.62,0.74) 21.47 1.592 13.49 0.14 89.7 
ACCESS to LLIN (%HH with an LLIN) 1041 0.898 0.0253 (0.84,0.94) 7.26 2.081 3.49 0.14 18.6 
ACCESS to LLIN (% HH with 1 net per 2) 1041 0.368 0.0307 (0.31,0.43) 4.20 1.388 3.03 0.12 18.6 
Caregiver knowledge about SMC 1068 7.0 0.2715 (6.5,7.6) 7.82 1.292 6.05 0.24 22.1 
Reported CHW adherence to guidelines 1068 7.6 0.1259 (7.3,7.8) 12.23 1.080 11.32 0.62 17.7 
SMC directly observed 1125 0.971 0.0128 (0.93,0.99) 6.48 1.253 5.17 0.13 32.1 
Interval between cycle 1 and cycle 2 1261 33.6 0.1424 (33.3,33.9) 12.99 1.183 10.99 0.39 26.5 
Interval between cycle 2 and cycle 3 1231 31.9 0.1319 (31.6,32.1) 11.15 1.070 10.42 0.38 26.1 
Interval between cycle 3 and cycle 4 686 32.9 0.4220 (32.0,33.7) 17.65 1.106 15.97 0.61 25.6 
SMC card at survey 1893 0.671 0.0385 (0.59,0.74) 12.72 1.397 9.11 0.24 34.2 
The rate of homogeneity, roh, was calculated as (Deffcluster-1)/(b-1), where Deffcluster is the design effect due to clustering, calculated from the 
overall design effect, and the design effect due to weighting, Deffclustering= Deffoverall/ Deffweighting, and b is the weighted mean cluster size, 
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